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HYPERCHOLESTEROLEMIA and CVD RISK 
 
Several epidemiological studies revealed lipid disorders, and in particular 
hypercholesterolemia, as one of the major risk factors for the onset and 
development of cardiovascular disease (CVD) (Prospective Studies et al., 2007, 
Kannel et al., 1961, Gordon et al., 1977, Yusuf et al., 2004). High cholesterol 
plasma levels lead, in fact, to Low Density Lipoproteins (LDL)-cholesterol 
accumulation in artery wall, predisposing to inflammation and consequently to 
the development of the atherosclerotic plaque underlying CVD. CVD is 
considered one of the leading causes of death in western countries (Go et al., 
2014). Clinical risk factors, such as hypertension and high cholesterol, are the 
main targets of primary prevention in clinical practice. Hypolipidemic therapies, 
such as statins, lowering LDL-cholesterol reduced CVD related morbidity and 
mortality in primary and secondary prevention (Baigent et al., 2005) in 
association with a low cholesterol and saturated fat content diet. However, some 
patients, in particular patients with familial hypercholesterolemia, fail to reach 
the recommended LDL-cholesterol levels with statins (Rader et al., 2003) or 
develop statin intolerance leading to myopathy, or do not lower CVD risk as a 
consequence of other lipid disorders (Bhatt et al., 2006, Barter et al., 2007, 
Holmes et al., 2014). Treatment with drugs displaying different mechanisms of 
action, such as bile acid (BA) sequestrants and fibrates is available but, although 
the improvement in lipid profile, they do not seem to ameliorate CVD risk 
(Drexel, 2009). In this scenario the discovery of new therapeutic approaches and 
consequently of new pharmacological targets is desiderable to attain the 
reduction of CVD risk. In light of these evidences, it is therefore fundamental to 
deepen the molecular mechanisms underlying the maintenance of cholesterol 
and lipid homeostasis. 
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CHOLESTEROL 
 
GENERAL CHARACTERISTICS 
Cholesterol is a molecule consisting of 27 carbon atoms characterized by a 
tetracyclic steroid nucleus formed by four linked hydrocarbon rings, 1 made by 5 
carbon atoms and the other 3 made by 6 carbon atoms, in the “chair” 
conformation. The cyclopentanoperhydrophenanthrenic nucleus is unsaturated at 
position 5-6 with an alkene group and it has a rigid planar structure with a 
flexible tail, consisting of a isooctyl side chain at carbon 17. Cholesterol is an 
amphipathic molecule due to its polar hydrophilic hydroxyl group at carbon 3 and 
to the non-polar lipophilic hydrocarbon body (Fig. 1). The peculiar structure of 
cholesterol confers the ability to intercalate between phospholipids in lipid 
bilayers of the cellular membrane, interacting both with the polar heads and 
with the apolar tails of phospholipids, thus modulating membrane fluidity and 
permeability.  
 
 
Fig.1: Cholesterol structure 
Polar head
Steroid
nucleus
Alkyl side 
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Introduction 
 
  
10 
Cholesterol is, in fact, an essential component of cellular membranes, 
nervous fibers and myelin sheaths. Moreover, it is the precursor of  BA, steroidal 
hormones and vitamin D. Cholesterol is the most abundant sterol in animals 
tissues; in plants it is a minor component only of a complex mixture of 
structurally related 'phytosterols', such as stigmasterol. Prokaryotes lack 
cholesterol entirely, apart from a few species that acquire it from eukaryotic 
hosts. Supply of cholesterol is ensured by the endogenous biosynthetic pathway 
and it is synthesized mainly in the liver by the mavalonate pathway, whereas the 
remaining amount derives from the diet. Since it is not readily and completely 
biodegradable, cholesterol does not serve as a fuel for animal tissues. Animals, in 
fact, lack the enzymes necessary to catabolize steroid rings constituting 
cholesterol so that high levels of cholesterol in the blood are detrimental as they 
may lead to excessive accumulation in vessel walls, predisposing to the 
development of pathological conditions such as atherosclerosis and myocardial 
infarction. The major route of cholesterol elimination from the intact organism is 
its conversion to BA or its secretion into bile. 
 
CHOLESTEROL HOMEOSTASIS 
Biosynthesis and catabolism of cholesterol occur mainly in the liver. 
Cholesterol biosynthesis is a highly complex process of about thirty different 
enzymatic reactions and it is regulated by an elegant system of feedback 
inhibition, which senses cholesterol intracellular levels and subsequently 
modulates the expression of the key proteins involved in cholesterol homeostasis 
(Ye and DeBose-Boyd, 2011). Cytosolic acetyl-CoA in hepatocytes is the precursor 
of cholesterol synthesis passing through the formation of the important 
intermediate mevalonic acid (Russell and Setchell, 1992). Mevalonate is 
synthesized from β-hydroxy-β-methyglutaryl-CoA (HMG-CoA) through a reaction 
catalyzed by HMG-CoA reductase, which is the rate limiting enzyme of 
cholesterol biosynthesis localized in the endoplasmic reticulum.  Recently, it has 
been demonstrated that squalene epoxidase (SQLE) may be a further control 
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point in cholesterol synthesis (Gill et al., 2011). HMGCoA reductase activity is 
regulated by several factors: post translational modifications, protein half-life 
modulation and regulation of gene transcription. Post translational modifications 
are mediated by glucagon and insulin that induce respectively 
phosphorylation/dephosphorylation events leading to the inhibition/activation of 
the enzyme (Beg and Brewer, 1982). Some metabolites of mevalonate pathway, 
such as a non-sterol isoprenoid signal derived from farnesyl diphosphate (FPP) 
and 24,25-oxidolanosterol, modulate HMGCoA reductase half-life (Gardner et al., 
2001). Peculiar sequences, Sterol Regulatory Element (SRE) localized on HMGCoA 
reductase, regulate gene transcription. Sterol Regulatory Element Binding 
Protein (SREBP), sensitive to intracellular cholesterol levels, binds SRE and 
induces gene transcription (Hua et al., 1993). At low cholesterol levels, in fact, 
insulin sensitive gene 1 (INSIG-1) dissociates from SREBP/SREBP Cleavage 
Activating Protein (SCAP) complex and it is degraded; the complex can migrate 
into the Golgi apparatus where SREBP is activated by sequential cleavages. 
Active SREBP translocates into the nucleus binding SRE sequences thus activating 
cholesterol synthesis (Ye and DeBose-Boyd, 2011). On the other hand, when 
intracellular cholesterol levels increase SCAP is inhibited and consequently 
cholesterol synthesis is blocked (Goldstein and Brown, 1987).  
Due to its insoluble nature cholesterol cannot dissolve in the blood, 
therefore it must be transported to different tissues by carriers called 
lipoproteins consisting of apolipoprotein core, phospholipids, cholesterol, 
triacylglycerols and steryl esters. Apolipoproteins associated with lipids form 
different classes of lipoproteins with hydrophobic lipids inside and hydrophilic 
side chain outside. Due to the different composition in lipids and proteins there 
are different density lipoproteins: chylomicrons, very low density lipoproteins 
(VLDL), low density lipoproteins (LDL), intermediate density lipoproteins (IDL) 
and high density lipoproteins (HDL). Cholesterol is esterified in the hepatocytes 
by acyl-CoA-cholesterol-acyltransferase (ACAT), transferring an acyl group from 
CoA to the hydroxyl group of cholesterol. This more hydrophobic form of 
cholesterol can be stored in lipid droplet in the liver or assembled in VLDLs. 
Introduction 
 
  
12 
Through the blood stream VLDLs delivered from the liver reach tissues. During 
this process they increase cholesterol content and are converted to LDLs. LDLs 
are internalized into the cell by the LDL-receptor (LDLR) delivering cholesterol 
inside the cell. In contrast, HDLs are the mediators for reverse cholesterol 
transport, collecting cholesterol from peripheral tissues and bringing it back to 
the liver. Nascent lipid poor HDL particles, also known as prebeta-HDL, collect 
free cholesterol and phospholipids from peripheral tissues; lecithin-cholesterol 
acyl transferase (LCAT) esterifies cholesterol forming HDL2 particles. Finally they 
reach the liver via Scavenger Receptor B1 (SR-B1) (Kingwell et al., 2014). 
Elimination of cholesterol from the body is achieved only promoting its 
conversion to BA. In fact, approximately one third of daily cholesterol produced, 
both endogenous and exogenous, is eliminated as fecal bile acids and BA 
biosynthesis represents quantitatively the most important pathway to maintain 
cholesterol homeostasis in mammals. In addition, cholesterol is eliminated as 
such through the bile. 
 
BILE ACIDS 
 
BA are steroid acids secreted by parenchimal cells in the biliary duct and 
stored in the gallbladder, from which they are released in the duodenum after 
hormonal stimuli. In the intestine BA act as powerful detergents or emulsifying 
agents to aid the digestion and absorption of dietary cholesterol, lipids, fat 
soluble vitamins (A, D, E, K) and other essential nutrients and to prevent the 
precipitation of cholesterol in bile. BA return to the liver via the enterohepatic 
circulation through the portal vein. Approximately 95% of the non-conjugated 
bile acids are reabsorbed passively throughout the small and large intestines 
(Hofmann and Hagey, 2008). This continuous flux of BA between the liver and the 
intestine requires several BA transporters (Alrefai and Gill, 2007). For instance, 
bile salt export pump (BSEP) mediates the release of BA into the bile across the 
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canalicular membrane, while apical sodium-dependent bile acid transporter 
(ASBT) and organic solute transporter (OSTα-OSTβ) reabsorb BA from the ileum, 
and finally sodium-taurocholate cotransporter polypeptide (NCTP) extracts BA 
from the portal blood (Dawson et al., 2009). A small amount of BA is lost in the 
feces but it is reintegrated by de novo synthesis, therefore in the steady state 
the fraction of bile acid pool that is excreted from the body each day is replaced 
by an equal amount of newly synthesized bile acid. Cholesterol reabsorbed from 
intestine in the bile is instead only 50%. In light of these processes the 
pharmacological interruption of the enterohepatic circulation of BA with BA 
sequestrants has been used as an effective strategy for lowering plasma LDL-
cholesterol in the treatment of atherosclerosis. 
Bile salts are hydrophilic on one side and hydrophobic on the other side 
consequently, they aggregate around lipid droplets to form micelles, with the 
hydrophobic sides towards the fat and hydrophilic sides facing outwards. The 
hydrophilic sides are negatively charged, and this charge prevents fat droplets 
coated with bile from re-aggregating into larger fat particles. BA release is 
regulated by hormones that are in turn induced by food: when the chyme enters 
the duodenum, low pH value induces secretin that stimulates pancreatic release 
of HCO3
- in the small intestine to reach pH 7; secretin promotes bile secretion 
from hepatocytes. Moreover, chyme in the duodenum causes cholecystokinin 
release that stimulates gallbladder emptying. 
Cholesterol conversion to BA requires at least 17 enzymes and occurs in 
multiple intracellular compartments including cytosol, endoplasmic reticulum, 
mitochondria, and peroxisomes. Two different BA biosynthetic pathways have 
been identified: the “classic” or “neutral” pathway , exclusively hepatic, and 
the “alternative” or “acidic” pathway whose reaction may also take place in 
extrahepatic cells (Martin et al., 1993). The most important BA present in the 
bile are cholic acid and chenodeoxycholic acid. These primary BA can be 
converted by microbiota in deoxycholic and lithocholic acid respectively. About 
98% of BA are conjugated with glycine or taurine in the liver generating bile salts 
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(Johnson et al., 1991), the most abundant constituent of bile together with 
cholesterol and lecithin.  
 
BILE ACID BIOSYNTHESIS: THE “CLASSIC” or “NEUTRAL” PATHWAY 
The “classic” or “neutral” pathway occurs only in the liver by more than 
ten different enzymes located in different subcellular compartments of the 
hepatocyte. It is also known as “neutral” since the intermediates mainly 
generated in this pathway are neutral sterols. The “classic” pathway is initiated 
by CYP7A1, the major check-point and the rate limiting enzyme of BA 
biosynthesis (Myant and Mitropoulos, 1977), which catalyzes cholesterol 
hydroxylation at the 7α position. CYP7A1 belongs to cytochrome P450 
superfamily and it is located in the endoplasmic reticulum. NADPH, O2 and the 
electron transport chain of the cytochrome P450 take part in the esoergonic and 
irreversible reaction. 3β-hydroxy-C27-steroid dehydrogenase/isomerase (3β-HDS) 
converts 7α-hydroxycholesterol in 7α-hydroxi-colest-4-ene-3-one, precursor both 
of chenodeoxycholic and of cholic acid. 12α-hydroxylase (CYP8B1), an enzyme 
localized in the endoplasmic reticulum, converts 7α-hydroxi-colest-4-ene-3-one 
in 7α,12α-dihydroxy-colest-4-ene-3-one (Chiang, 1998). 4-3-ossosteroid-5β-
reductase and 3α-hydroxysteroid dehydrogenase (HDS) converts these 
intermediates in 5β-cholestan-3α,7α-diol to synthesize chenodeoxycholic acid 
(CDCA), and in 5β-cholestan-3α,7α,12α-triol to synthesize cholic acid (CA). Their 
side chain is finally oxidized to a carboxylic group by sterol 27-hydroxylase 
(CYP27A1), a mitochondrial enzyme that leads to the formation of CDCA and CA 
respectively (Björkhem et al., 1992). After their synthesis primary BA are then 
conjugated with taurine or glycine before being secreted into bile. (Fig. 2) 
 
BILE ACID BIOSYNTHESIS: THE “ALTERNATIVE” or “ACIDIC” PATHWAY 
CYP27A1 catalyzes the first reaction of this biosynthetic pathway. This 
enzyme is the only member of the CYP27 cytochrome P450 superfamily and it is 
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localized in the inner mitochondrial membrane of endothelial cells, fibroblasts 
and macrophages (Martin et al., 1993). CYP27A1 plays an important role in the 
extrahepatic cholesterol disposal (Lund et al., 1996): it promotes extrahepatic 
cholesterol conversion to 27-hydroxycholesterol and in 3β-hydroxy-5-
cholestenoic acid that released in the blood stream are picked up by hepatocytes 
and used for BA biosynthesis. After the hydroxylation at 27 position, another 
hydroxylation occurs at 7α position catalized by oxysterol 7α-hydroxylase 
(CYP7B1) (Schwarz et al., 1997). The following reactions take place in the liver 
and they are catalyzed by the same enzyme of the “classic” pathway. The most 
abundant product of the “alternative” pathway is CDCA. (Fig.2) 
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Fig.2: Classic and anternative biosynthetic pathway of BA biosynthesis 
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CHOLESTEROL 7α-HYDROXYLASE (CYP7A1) 
 
Cholesterol 7α-Hydroxylase (CYP7A1) is a 57 kDa enzyme consisting of 503 
or 504 aminoacidic residues respectively in rats and in humans (Ogishima et al., 
1987, Chiang et al., 1990). CYP7A1 is anchored in the membrane of endoplasmic 
reticulum by an N-terminal hydrophobic region, and possesses a binding region 
for heme and a sterol binding site; moreover the aromatic aminoacid rich region 
is important for electron transfer; these regions are conserved in humans, rats 
and hamsters (Crestani et al., 1993). 
CYP7A1 gene was cloned in rats (Jelinek and Russell, 1990), humans (Wang 
and Chiang, 1994), hamsters (Crestani et al., 1993) and mice (Tzung et al., 
1994). In hamsters, rats and humans gene length is about 11Kb, made of 6 exons 
and 5 introns, and their sequence is high conserved among species. In humans 
only a single copy of the enzyme is present on the chromosome 8 in centromeric 
region q11-q12 (Cohen et al., 1992). CYP7A1 gene, differently from other CYP450 
possessing 7-13 exons, contains only 6 exons, suggesting that the evolutionary 
origin of this gene is rather old. 
CYP7A1-/- mice show hyperkeratosis, hypercholesterolemia, 
hypertriglyceridemia, behavioural and vision defects due to the inability to 
assume liposoluble vitamins (Pullinger et al., 2002, Ishibashi et al., 1996). On the 
contrary, it has been demonstrated that overexpression of CYP7A1 gene in 
hamsters by adenoviruses, decreases LDL cholesterol in animals fed both chow 
and high fat diet. By using adenovirus-mediated overexpression in 
hypercholesterolemic mice lacking the LDL receptor it was shown that Cyp7a1 
dramatically reduced serum cholesterol levels and improved the ratio of high-
density lipoproteins/LDL (Spady et al., 1998). An interesting paper by Li and 
coworkers showed that mice overexpressing Cyp7a1 in the liver were resistant to 
HFD–induced obesity, fatty liver, and insulin resistance. These mice displayed 
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increased hepatic cholesterol catabolism and an increased bile acid pool, 
increased secretion of hepatic VLDL but maintained plasma triglyceride. 
Moreover, the authors observed induction of fatty acid oxidation genes in the 
brown adipose tissue in association with increased body energy expenditure in 
Cyp7a1-tg mice (Li et al., 2010b), linked to an increased hydrophobic BA pool (Li 
et al., 2011b). Improvement of energy expenditure in these mice is consistent 
with a paper recently published demonstrating that BA act also on TGR5, another 
BA receptor localized in brown adipose tissue, whose stimulation leads to 
deiodinase 2 (D2) activation causing increase of 3,5,3′-tri-iodothyronine (T3) and 
consequently uncoupled protein 1 (UCP1) induction, a well known activator of 
non-shivering thermogenesis (Watanabe et al., 2006).  
 
CHOLESTEROL 7α-HYDROXYLASE REGULATION: the role of BA 
CYP7A1 gene is regulated mainly at the transcriptional level in response to 
BA, cholesterol and hormones and is fundamental for the maintenance of 
cholesterol homeostasis (Ramirez et al., 1994). The main regulatory mechanism 
of CYP7A1 transcription is the feedback regulation operated by BA returning to 
the liver via the enterohepatic circulation. The sequence responsible of this 
response was first discovered by Stroup and co-workers (Stroup et al., 1997) and 
it is localized at nucleotides−148/−129 relative to the transcription start site of 
the rat gene. This sequence is highly conserved in all CYP7A1 from different 
species and was named BARE (bile acid-responsive element). The BARE is the 
binding site of some nuclear receptors such as the orphan nuclear receptor 
hepatocyte nuclear factor 4 (HNF4), and the mouse homologue liver receptor 
homologue-1 (LRH-1) (Crestani et al., 1998). A further characterization of this 
region showed that the rat CYP7A1 proximal promoter contains 2 BAREs, with 
high sequence similarity. BARE-I corresponds to the LXRE (Lehmann et al. 1997), 
and BARE-II has been shown to be the binding site for LRH-1 and HNF4, which are 
required for hepatic basal expression of CYP7A1 (Nitta et al., 1999). First 
evidences of CYP7A1 feedback regulation mechanism operated by BA appear in 
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the literature in 2000, with the discovery of the mechanism of action of bile acid 
receptor farnesoid X receptor (FXR, NR1H4). In the liver (Fig. 3A) BA interact 
with their nuclear receptor FXR, inducing the expression of the orphan nuclear 
receptor small heterodimer partner (SHP, NR0B2), an atypical orphan receptor 
lacking the DNA binding domain. SHP heterodimerizes with LRH-1 and represses 
the transcription activity of the receptor and consequently the expression of 
CYP7A1 (Goodwin et al., 2000) (Lu et al., 2000c).  
 
Fig.3: BA-induced activation of FXR in the liver (A) and in the intestine (B) 
 
An apparently contradictory study by Kerr and coworkers showed that in 
mice lacking Shp gene, BA negative feedback on their own synthesis and 
particularly on CYP7A1 gene was impaired but not completely eliminated. This 
evidence revealed the existence of other compensatory repression pathways of 
bile acid signaling (Kerr et al., 2002). Further investigations, in fact, lead to the 
discovery of additional mechanisms adopted by BA to regulate CYP7A1 
transcription. Subsequently, it was demonstrated that in the intestine (Fig. 3B), 
FXRE
FXRRXR
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B
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FXR activation by BA induces the release of fibroblast growth factor 15/19 
(FGF15 in mouse or FGF19 in human), which activates hepatic FGF receptor 4 
(FGFR4) signaling to inhibit CYP7A1 transcription and BA biosynthesis (Inagaki et 
al., 2005). Moreover, De Fabiani and coworkers in 2001 demonstrated that BA 
decrease CYP7A1 transcription in a FXR/SHP-independent manner, via the 
mitogen-activated protein kinase pathway, which depresses the transactivation 
potential of HNF-4. Moreover, they showed that the pro-inflammatory cytokine 
TNFα inhibits CYP7A1 through the same mechanism (De Fabiani et al., 2001). 
Further investigations, allowed the same authors to better define the molecular 
events underlying CYP7A1 repression; they found that BA induce the dissociation 
of a co-activator complex from HNF-4 (De Fabiani et al., 2003), interfering with 
the recruitment of PPARγ co-activator-1α (PGC-1α) and cAMP-response element 
binding protein-binding protein (CBP; p300), two transcriptional coactivators, to 
CYP7A1 promoter. Since the selective FXR ligand, GW4064 does not affect the 
transactivation potential of HNF-4, the authors demonstrated that this 
dissociation is not mediated by FXR/SHP. 
These evidences stimulated several studies to investigate chromatin 
remodeling induced by BA (Fang et al., 2007, Kemper et al., 2004, Ponugoti et 
al., 2010). An interesting study conducted in our laboratory analyzed chromatin 
remodeling elicited by BA and showed the dissociation of PCG-1α and CBP from 
CYP7A1 promoter and recruitment of Histone Deacetylases (HDACs) and 
corepressors after BA treatment in the human liver cell line HepG2. This effect 
occurs earlier than the FXR/SHP-mediated repression, demonstrating also that 
the feedback repression of CYP7A1 transcription by BA is a multiple process 
involving several mechanisms (Mitro et al. 2007). In particular, it was shown that 
BA induce the translocation of HDAC7 from cytoplasm to nucleus and the 
sequential recruitment of HDAC 7, 3, and 1, and of the corepressors Silencing 
Mediator of Retinoid and Thyroid receptors-α (SMRT-α) and N-CoR1 forms a 
repressive complex on CYP7A1 promoter that leads to the repression of CYP7A1 
gene transcription (Fig. 4). 
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Fig. 4: BA-induced chromatin remodeling of CYP7A1 promoter 
Adapted by Mitro, Frontiers in Bioscience 13, 6276-6288, May 1, 2008 
 
CHOLESTEROL 7α-HYDROXYLASE REGULATION: other regulatory factors 
As mentioned above, BA are important actors in the digestive processes 
and in the absorption of dietary lipids. Therefore, it is reasonable to assume that 
their synthesis can be regulated by the fasted-to-fed cycle. In mice CYP7A1 
expression increases in the fasting state and returns to normal upon feeding (De 
Fabiani et al., 2003), suggesting the modulation by the two principal hormones 
regulating fasting–feeding cycle, insulin and glucagon. In particular, insulin 
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inhibits CYP7A1 in different species (De Fabiani et al., 2000, Crestani et al., 
1998). Moreover, it has been demonstrated that physiological concentrations of 
insulin rapidly increase mRNA levels in primary human hepatocytes but, on the 
contrary, an extended treatment inhibits CYP7A1 expression. This occurs because 
the insulin-regulated transcription factors, forkhead box O1 (FoxO1) and SREBP-
1c, inhibit HNF-4 and PGC-1α transactivation of the CYP7A1, while the rapid 
insulin-induced activation of the p38 kinase pathway increases HNF-4α and could 
lead to CYP7A1 induction in the shorter time (Xu et al., 2007). On the other side, 
during fasting glucagon activates cAMP signalling inhibiting CYP7A1 transcription 
in primary rat and human hepatocytes (Song and Chiang, 2006).  
Furthermore, it has been demonstrated that CYP7A1 expression is also 
regulated by thyroid hormones (Ness et al., 1990), extrogens (Kushwaha and 
Born, 1991) and inibite by the proinflammatory cytochines TNFα e IL-1β (De 
Fabiani et al., 2001). The activity of CYP7A1 withstands diurnal variation in rat 
livers and in rodents it is increased during the night whereas decreased during 
the day (Gielen et al., 1969). In humans, CYP7A1 undergoes daytime changes as 
well but it is independent of food intake and opposite from the circadian rhythm 
of cholesterol synthesis (Gälman et al., 2005).  
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EPIGENETICS 
Inheritable influence on gene activity that modifies chromatin structure 
without changes in DNA sequence is known as epigenetics. Nucleosomes are the 
building blocks of chromatin and histone octamers wrapped twice by DNA 
constitute their core structure in eukaryotic cells. Chromatin is a dynamic 
structure that adopts a locally accessible and transcriptionally active form, also 
known as euchromatin during the activation of gene transcription. Alternatively, 
when chromatin is in a highly condensed and transcriptionally inhibited state, is 
referred to as heterochromatin (Richards and Elgin, 2002) (Fig. 5). 
 
Fig. 5: Conformational changes of chromatin induced by histone modifications 
On the left, euchromatin represents acetylated and transcriptionally active state. 
On the right, DNA methylation and histone deacetylation induce chromatin  
packaging (heterochromatin) making it less accessible to transcriptional factors. 
(Ferrari et al., 2012) 
 
The main epigenetic modifications include DNA methylation and histone 
modifications (Vaillant and Paszkowski, 2007). Posttranslational modifications,  
including acetylation, ADPribosylation, methylation, phosphorylation, and 
ubiquitination occurring at amino acids in the N-terminal of histone tails strongly 
regulate chromatin packaging and consequently gene expression. One of the 
most studied post-translational modifications is acetylation of lysine residues of 
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histone tails resulting from the balance between HAT (histone acetyltransferase) 
and HDAC activity (Grunstein, 1997b); acetylation carried out by HAT increases 
the distance between DNA and histones and the accessibility of transcription 
factors to gene promoter regions, while deacetylation operated by HDACs 
induces chromatin packaging thus reducing the accessibility of transcription 
factors to local chromatin regions (López-Rodas et al., 1993a). 
 
HISTONE DEACETYLASES 
 
Eukaryotic HDACs belong to an ancient family of proteins comprising two 
subfamilies with different HDAC activity: the classical HDAC family and the 
sirtuins family (de Ruijter et al., 2003). Mammalian HDACs are listed into four 
classes based on their homology with yeast HDACs (Haberland et al., 2009) (Fig. 
6). The classical HDAC family consists of eleven Zn2
+-dependent enzymes 
harboring a Zn2
+ ion in their catalytic pocket (Ferrari et al., 2012). They are 
divided in three classes: 
 Class I (HDAC1, 2, 3, and 8) closely related to the yeast transcriptional 
regulator Rpd3, are ubiquitously expressed and are mainly localized in the 
nuclear compartment where they exert the most relevant histone deacetylase 
activity.  
Class II (HDAC4, 5, 6, 7, 9, and 10) similar to the yeast Hda1 localize in the 
cytoplasm, shuttling into the nucleus in response to specific cellular signals. 
Class IIa HDACs are characterized by post-translational regulation such as 
phosphorylation that determines their cytosolic localization, whereas 
dephosphorylation of Class IIa HDACs enables their translocation to the nucleus; 
Class IIa HDACs carry a large N-terminal with conserved binding sites for the 
transcription factor myocyte enhancer factor 2 (MEF2) and the chaperone protein 
14-3-3. First of all, upon  phosphorylation by different kinases, the 
calcium/calmodulin-dependent protein kinase and protein kinase D, class IIa 
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HDACs bind 14-3-3 and translocate from the cytoplasm to the nucleus (Passier et 
al., 2000, Vega et al., 2004, Lu et al., 2000a). When interacting with class IIa 
HDACs, MEF2 acts as transcriptional repressor; in contrast, its dissociation from 
HDACs promotes the recruitment of the histone acetyltransferase p300 and the 
conversion of MEF in a transcriptional activator (Lu et al., 2000b, Youn et al., 
2000, Wang et al., 1999, Miska et al., 1999, Sparrow et al., 1999). Class IIa 
HDACs feature only minimal histone deacetylase activity due to a swap of a key 
tyrosine residue in the catalytic domain with a histidine (Lahm et al., 2007); 
nonetheless, they act as scaffold molecules to recruit class I HDACs. Class IIb 
HDACs are localized in the cytoplasm and act mainly on non-histone substrates 
such as cytoskeletal and transmembrane proteins (Haberland et al., 2009). 
Class IV (HDAC11) role is still not clearly understood (Gregoretti et al., 
2004). 
Fig. 6: Superfamily of mammalian histone deacetylases 
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(Ferrari et al., 2012) 
 Class III HDACs comprises the sirtuins family; they are sensitive to changes 
in the intracellular NAD+/NADH ratio and they rely upon NAD+ hydrolysis for their 
deacetylase activity. In mammals, sirtuins regulate several functions, ranging 
from the control of cellular stress to energy metabolism (Finkel et al., 2009) 
(Fiorino et al., 2014). Sir2 homolog family in mammals comprises seven proteins 
with different localizations and functions and are classified in four classes based 
on phylogenetic analysis: SIRT1, 2, and 3 belong to class I, SIRT4 to class II, SIRT5 
to class III, and SIRT6 and 7 to class IV (Frye, 2000). 
 
HISTONE DEACETYLASES INHIBITORS 
 
From the structural point of view, synthetic HDAC inhibitors can be 
classified in four groups: short-chain fatty acids, hydroxamic acids, benzamide 
derivatives, and cyclic peptides. We will briefly highlight the main features of 
each class addressing interested readers to specific reviews on the topic (Mai and 
Altucci, 2009). 
Short-chain fatty acids such as sodium butyrate, sodium phenylacetate, 
phenylbutyrate and valproate, are active at millimolar concentrations and can be 
defined pan-inhibitors although they seem to be less active against class IIb 
HDACs. The mechanism by which this class of compounds inhibits HDACs has not 
been fully elucidated. 
The first compound bearing a hydroxamic acid moiety to be described as 
HDAC inhibitor was trichostatin A (TSA), which is produced by Streptomyces 
hygroscopicus and displays antifungal activities. However, the prototype 
compound of this class is suberoylanilide hydroxamic acid (SAHA) that was 
approved by the US FDA in 2006 for cutaneous manifestations of cutaneous T-cell 
lymphoma (Fig. 7). Hydroxamic acids are usually active in the nanomolar range 
and inhibit HDACs by complexing the zinc cation present in the catalytic pocket 
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of the enzyme with the hydroxamate group. Many evidences suggest HDAC 
inhibitors as an interesting approach in cancer therapy. DNA damage response is 
in fact modulated by the acetylation status of histone and non-histone proteins 
and HDACs protect cancer cells from genotoxic insults. Therefore, HDAC 
inhibitors can silence DNA repair pathways, inactivate non-histone proteins that 
are required for DNA stability and induce reactive oxygen species and DNA 
doublestrand breaks (Rajendran et al., 2011). 
The cyclic peptide romidepsin (formerly known as FK-228) is produced by 
Chromobacterium violaceum and shows higher inhibitory activity toward class I 
HDACs, with IC50 in the nanomolar range. In the cellular reducing environment, 
this compound is converted into its reduced form that can interact with the 
enzyme active site. This molecule was very recently approved by US FDA for 
patients with cutaneous T-cell lymphoma. 
Finally, MS-275 is the lead compound of the benzamide derivatives series. 
This compound is highly active against class I HDACs and almost completely 
inactive toward class II enzymes (Fig. 7). 
In addition, several natural compounds have been added to the list of 
HDAC inhibitors in the last years. The beneficial effects of dietary 
isothiocyanates and allyl sulfides on human health, and in particular their cancer 
chemopreventive effects, have been known for a long time (Zhang and Talalay, 
1994) however, only recently their positive actions have been linked with 
epigenetic mechanism.  
A major understanding of HDAC active site structure and of the molecular 
features required to inhibit HDAC catalytic activity, in particular the presence of 
a spacer “arm” that allows the entry into the catalytic pocket and of a 
functional group interacting with the zinc cation, led to the reconsideration of 
the biological activity of several natural compounds.  
Sulforaphane (SFN) is one of the most characterized isothiocyanates found 
in vegetables. It derives from the glucosinolate glucoraphanin present in 
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cruciferous vegetables, such as broccoli and broccoli sprouts. Like other 
isothiocyanates, it is metabolized via the mercapturic acid pathway to active 
metabolites, among which SFN-cysteine displays a good fit for HDAC active site 
according to computer modeling predictions (Nian et al., 2009). Indeed, the 
effects of SFN in vitro and in vivo systems are associated with increased global 
histone acetylation (Myzak et al., 2004, Myzak et al., 2006a, Myzak et al., 
2006b). 
Allyl compounds are garlic components comprising diallyl disulfide and S-
allyl mercaptocysteine, which are both converted into the active metabolite allyl 
mercaptane. Docking simulation revealed a good fit between allyl mercaptane 
and HDAC active site, consistent with accumulation of acetylated histones and 
growth arrest in cancer cells treated with the active metabolite at micromolar 
concentrations (Nian et al., 2008). 
Finally, sodium butyrate that we mentioned before as a synthetic HDAC 
inhibitor, should also be included in the list of naturally occurring inhibitors since 
it is generated during the fermentation of dietary fibers in the large intestine 
(Cummings and Englyst, 1987). 
HDACs inhibitors might represent a novel and promising therapy in 
patients with heart failure (McKinsey et al., 2000) since HDACs play an important 
role in control of several cardiac events such as hypertrophy (Antos et al., 2003), 
autophagy (Cao et al., 2011), contractility (Gupta et al., 2008). Moreover, other 
recent evidences underline the importance of tubulin acetylation mediated by 
HDAC6 in the development of Huntington (Dompierre et al., 2007) and Parkinson 
diseases (Outeiro et al., 2007). Based on these results, the HDAC class II 
selective inhibitors have been theorized as new avenues for therapeutic 
intervention in some neurodegenerative disorders (Li et al., 2011a). Given the 
role of different HDACs in metabolic regulation, it is possible that in the future 
some specific inhibitors may find some clinical applications in metabolic 
disorders. 
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Fig. 7: Histone Deacetylases inhibitors 
SAHA: Pan inhibitor of HDACs inhibits both class I and II HDACs; MS275: class I 
selective HDAC inhibitor  and MC1568 class II selective HDAC inhibitor.
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Hypercholesterolemia is one of the main risk factors for the onset and 
development of cardiovascular disease (CVD) and atherosclerosis. Nowadays 
several therapies are being used to reduce the rate of morbidity and mortality 
associated with hypercholesterolemia, targeting both the endogenous cholesterol 
biosynthetic pathway and the uptake of exogenous cholesterol form the diet but 
some patients respond poorly to them or show some adverse effects. Therefore, 
it is necessary to better understand genetic and molecular mechanisms involved 
in the pathophysiological regulation of cholesterol homeostasis to devise new 
and innovative therapeutic approaches aimed at lowering plasma cholesterol 
levels and the associated CVD risk.  
Hepatic bile acid biosynthesis is quantitatively the chief metabolic pathway 
to maintain cholesterol balance in mammals. It has been demonstrated that 
increased bile acid synthesis strengthens cholesterol removal from liver and 
decreases circulating low density lipoprotein (LDL) levels. Cholesterol 7α-
hydroxylase (CYP7A1) is the major check-point in the “classic” pathway of BA 
synthesis catalyzing the hydroxylation of cholesterol at the 7α position and it 
acts as the main regulator of bile acid biosynthesis, therefore it has deep impact 
on cholesterol homeostasis. The activity of this enzyme is mainly regulated at 
the transcriptional level by different bile acid-induced pathways which feedback 
inhibit CYP7A1 gene transcription. A peculiar role in this scenario is played by 
HDACs. In recent years, in fact, it has become clear that epigenetic 
modifications leading to chromatin remodeling affect metabolic homeostasis. In 
particular, HDACs have been involved in the regulation of BA biosynthesis genes. 
Mitro and coworkers in 2007 described an FXR-independent CYP7A1 inhibition 
mediated by the translocation of HDAC7 from cytoplasm to nucleus and the 
sequential recruitment of HDACs and corepressors elicited by BA on CYP7A1 
promoter, which is chronologically distinct from the FXR/SHP dependent 
regulatory pathway occurring at a later stage (Mitro et al., 2007). These 
observations highlight the crucial role of HDACs in the regulation of CYP7A1 
expression suggesting HDAC7 as a possible main actor in this regulatory pathway. 
Aim of the Study 
 
  
32 
Moreover, they observed that non-selective HDAC inhibitors, such as valproic 
acid (VPA) and trichostatin A (TSA), prevent the repressive effect of BA on 
CYP7A1 in vitro (Fig. 8a). In addition, in vivo these inhibitors increase Cyp7a1 
levels and fecal bile acid excretion as an index of increased BA biosynthesis (Fig. 
8b) leading to LDL-cholesterol reduction in a genetic model of 
hypercholesterolemia, such as LDL receptor knock out mice (Fig. 8C). 
 
 
 
Based on these evidences the central hypothesis is that HDACs are key 
regulators of CYP7A1 expression and consequently of cholesterol homeostasis, 
thence, the aim of my doctorate project has been to define the role of specific 
HDACs and corepressors in the regulatory mechanism of CYP7A1 gene 
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Fig. 8: Non-selective HDAC-i totally 
prevent BA repression on CYP7A1 
and reduce LDL cholesterol 
a) CYP7A1 mRNA levels after 
administration of VPA and TSA in 
vitro; b) Cyp7a1 mRNA levels (left 
side of the graph) and fecal BA 
excretion (right side of the graph) 
after administration of VPA and TSA 
in LDL-R KO mice; c) Plasma 
lipoprotein levels in LDL-R KO mice 
after treatment with saline solution 
(vehicle), VPA and TSA. 
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transcription and on cholesterol catabolism to BA and to confirm the central role 
of HDAC7 in this pathway in vivo. 
To address this goal I used different strategies: 
Class selective HDAC inhibitors in vitro and in vivo: 
I tested class selective HDAC-inhibitors in vitro and in vivo, in a human 
hepatoma reporter cell line harboring a human CYP7A1 minigene/luciferase 
reporter gene construct (HepG2 2.2.1 luc) and on C57BL/6J mice, respectively, 
with the aim to understand which class of HDACs played the predominant role in 
the regulatory pathway of CYP7A1. 
RNAi approach: 
To unravel the role of specific HDACs and corepressors and their single 
contribution in the modulation of CYP7A1 expression, I set up adenovectors 
expressing shRNA that silence HDACs in vitro and in vivo. 
Generation of a conditional KO mouse lacking liver HDAC7 (H7LivKO): 
It has been shown that HDAC7 can translocate from cytoplasm to nucleus in 
response to BA and that the inhibition of this translocation with the phosphatase 
inhibitor Caliculin A totally prevents BA repressive effect on CYP7A1 (Mitro et 
al., 2007), suggesting a key role of HDAC7 in the transcriptional regulation of this 
gene. Therefore, to better define the role of HDAC7 in CYP7A1 regulation and on 
cholesterol and lipid homeostasis in vivo, I generated a conditional KO mouse 
lacking hepatic Hdac7 (H7LivKO ) and I analyzed the metabolic features of 
H7LivKO mice on Western Diet, a diet enriched in cholesterol, in order to 
emphasize the effect of HDAC7 ablation on cholesterol and lipid metabolism. 
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CELL CULTURES  
 
HepG2 2.2.1 luc 
HepG2 2.2.1 luc cell line is produced by ATCC (American Type Culture 
Collection, Manassas, VA) and it is derived from the hepatocellular carcinoma 
cell line, HepG2. The parental cells were stably transfected at passage 48 with a 
human CYP7A1 minigene/luciferase construct. Luciferase reporter gene is 
upstream of hCYP7A1 promoter, inserted within exon 2 (Fig. 9). 
 
Fig. 9: Schematic representation of hCYP7A1 minigene/luciferase construct 
 
Manteinance medium: 
Dulbecco's Modified Eagle's Medium and Ham’s F12 (1:1) (Gibco, Life Tecnologies 
Paesley, Scotland) with fetal bovine serum to a final concentration of 10%, L-
Glutamine (Gibco, Life Tecnologies Paesley, Scotland), Pen/Strep (Gibco, Life 
Tecnologies Paesley, Scotland) and supplemented with 0,4 mg/ml G418. 
Temperature: 37.0°C 
Subculturing protocol: 
 Remove and discard culture medium. 
 
hCYP7A1
PROMOTER
INTRON1 LUC SV40pA INTRON2
EXON1 EXON2 EXON2
hCYP7A1
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 Briefly rinse the cell layer with 0.25% (w/v) Trypsin 0.53 mM EDTA solution 
(Gibco, Life Tecnologies Paesley, Scotland) to remove all traces of serum 
which contains trypsin inhibitor. 
 Add 3.0 ml of Trypsin-EDTA solution to flask and observe cells under an 
inverted microscope until cell layer is dispersed (usually within 5-7 
minutes). 
Note: To avoid clumping do not agitate the cells by hitting or shaking the 
flask while waiting for the cells to detach. Cells that are difficult to 
detach may be placed at 37°C to facilitate dispersal. 
 Add 7.0 ml of complete growth medium and aspirate cells by gently 
pipetting. 
 Add appropriate aliquots of the cell suspension to new culture vessels. 
Inoculate at a cell concentration between 1.5 X 105 and 1.0 X 106 viable 
cells/75 cm2. 
Incubate cultures at 37°C. 
Medium Renewal: Every 2/3 days. 
HDAC inhibitors treatment: 
Day 1: 
50000 cell/well were seeded in 96 well plates and incubate 24h at 37°C in DMEM 
F12 with 10% fetal bovine serum, 1% L-Glutamine, 1% Pen/Strep and 0,4 mg/ml 
G418. 
Day 2: 
O/N treatment with HDAC inhibitors (SAHA 2,5µM, MS275 2,5µM, MC1568 2,5µM) 
or 0,1%DMSO in the control wells, with or without CDCA 25µM in DMEM F12 with 
1% L-Glutamine, 1% Pen/Strep and 0,4 mg/ml G418medium without serum. 
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MS275 and MC1568 are provided by Prof. Antonello Mai, Università di Roma “La 
Sapienza”. SAHA by Cayman Michigan, USA. 
Day 3: 
96 well plates cells were lysed using briteliteTM plus (Perkin Elmer, Monza, Italy) 
and RLU were detected with EnVision (Perkin Elmer Waltham, MA). Data were 
normalized on the total protein amount by BCA assay (Pierce). 
Transfection protocol: 
Day 1: 
Preparation of transfection mix, final volume 1200µl consisting of:  
600µl of a solution containing siRNA 2 µM in DMEM F12 medium without Pen/Strep 
and serum; kindly mix and incubate 5 minutes RT. 
600µl of a solution containing 38µl DharmaFECT 4 siRNA Transfection Reagent (GE 
Healthcare Lafayette, CO) in DMEM F12 medium without Pen/Strep and serum; 
kindly mix and incubate 5 minutes RT. 
Mix together the solutions and incubate 20 minutes RT.  
Add the transfection mix to DMEM F12 medium with 10% serum, 1% L-glutamin 
and without Pen/Strep and 0,4 mg/ml G418 containing cells previously counted, 
till reaching a final volume of 12000 µl at 500000 cells/ml.  
Incubate the solution containing cells, medium and transfection mix for 30 
minutes and then seed 500000  cells/ml in 96 and 12 well plates. Incubate cells 
at 37°C for 24h. 
Day 2: 
Add DMEM F12 medium with 1% L-glutamin,  without serum, Pen/Strep and G418 
with or without 25 µM CDCA and incubate O/N at 37°C. 
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Day 3: 
RNA extraction of 12 well plates and Real Time PCR quantification of the target 
gene silenced by siRNA.  
96 well plates cells were lysed using briteliteTM plus (Perkin Elmer, Monza, Italy) 
and RLU were detected with EnVision (Perkin Elmer Waltham, MA). Data were 
normalized on the total protein amount by BCA assay. 
 
Hepa 1-6 
Hepa 1-6 is produced by ATCC (American Type Culture Collection, Manassas, VA) 
and it is a derivative of the BW7756 mouse hepatoma that arose in a C57/L 
mouse.  
Manteinance medium: 
Dulbecco's Modified Eagle's Medium Advanced with fetal bovine serum to a final 
concentration of 10%, 2% L-Glutamine, 1% Pen/Strep. 
Temperature: 37.0°C 
Subculturing protocol: 
 Remove and discard culture medium. 
 Briefly rinse the cell layer with 0.25% (w/v) Trypsin 0.53 mM EDTA solution 
to remove all traces of serum which contains trypsin inhibitor. 
 Add 3.0 ml of Trypsin-EDTA solution to flask and observe cells under an 
inverted microscope until cell layer is dispersed (usually within 5-7 
minutes). 
Note: To avoid clumping do not agitate the cells by hitting or shaking the 
flask while waiting for the cells to detach. Cells that are difficult to 
detach may be placed at 37°C to facilitate dispersal. 
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 Add 7.0 ml of complete growth medium and aspirate cells by gently 
pipetting. 
 Add appropriate aliquots of the cell suspension to new culture vessels. 
Inoculate at a cell concentration between 1.5 X 105 and 1.0 X 106 viable 
cells/75 cm2. 
Incubate cultures at 37°C. 
Medium Renewal: Every 2/3 days. 
Transfection protocol: 
Day 1: 
320000 cells per well are seeded in DMEM Advanced medium with 10% of serum, 
2% L-glutamin and 1% Pen/Strep. 
Day 2: 
Preparation of transfection mix, final volume 200µl consisting of:  
100µl of a solution containing siRNA 2 µM in DMEM Advanced medium without 
Pen/Strep and serum; kindly mix and incubate 5 minutes RT. 
100µl of a solution containing 4.8µl DharmaFECT 4 siRNA Transfection Reagent 
(GE Healthcare Lafayette, CO) in DMEM Advanced medium without Pen/Strep and 
serum; kindly mix and incubate 5 minutes RT. 
 Mix together the solutions and incubate 20 minutes RT. Add the mix to each well 
together with 1800 µl DMEM Advanced medium with 10% serum, 2% L-glutamin 
and without Pen/Strep. Incubate cells at 37°C for 6h. Change medium with DMEM 
Advanced medium with 10% serum, 2% L-glutamin and 1% Pen/Strep. Incubate at 
37°C per 48h. 
Day 4: 
RNA extraction and Real Time PCR quantification of the target gene silenced by 
siRNA. 
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PRIMARY HEPATOCYTES  
 
Isolation from mouse livers 
Mouse hepatocytes were isolated using a two-step collagenase perfusion 
method. Animals were first anhestesized with ketamin/xylazin (attachment IV of 
Directive 2010/6 3/UE), then liver has been in situ perfused by mean of caval 
vein incannulation (using a caliber 26 G needle) with Liver Perfusion Medium 
(Gibco, Life Tecnologies Paesley, Scotland) supplemented with 100UI of penicillin  
G/mL and 100μg of streptomycin/mL at 37 °C. Perfusion was carried on for 10 
minutes using a peristaltic pump  (Gilson, Middleton, USA) setted  at 15 ml/min 
of flow rate. Liver was then perfused for ten 10 minutes with Liver Digestion 
Medium (Gibco, Life Tecnologies Paesley, Scotland) at 37° C.  
Digested liver has been removed from mouse body, gallbladder has been 
eliminated and, under sterility conditions, was moved to a 10 cm petri dish with 
10 ml of Leibovitz L-15 medium (Sigma Aldrich St. Louis, MO, USA) added with 5% 
of fetal bovine serum (FBS).  
Liver has been disgregated with 2 microscopy glasses to allow the 
extraction of hepatocytes from parenchimal tissue, then to harvest completely 
the hepatocytes, 2 washes with 10 ml of Leibovitz's L-15 were carried on. The 
obtained suspension has been filtered through a plastic mesh with 100 µm pores 
and collected in a 50ml falcon tube.  
The test tube was then centrifuged at 1500 rpm for 2 minutes. 
Hepatocytes pellet was washed twice with 10 ml of Hepatocyte Wash Medium 
(Gibco, Life Tecnologies Paesley, Scotland) added with 100 UI of penicillin G/mL 
and 100 µg of  streptomycin/mL followed by a centrifugation at 1500 rpm for two 
minutes . The supernatant was eliminated after every rinse. Hepatocytes pellet 
was suspended with 10 mL Percoll 42% (Sigma Aldrich St. Louis, MO, USA) 
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(diluited in sterile phosphate buffer, PBS) and centrifuged at 1500 rpm for 2 
minutes: the cells that were still alive after the process were set in the bottom 
part of the tube. After removing the supernatant, another rinse was carried on 
with 10 mL of Hepatocyte Wash Medium added with 100 UI of penicillin G/mL and 
100 µg of streptomycin/mL. Vital hepatocytes were re-suspended in 10 mL of 
Hepatocyte Attachment Medium (HAM), Williams medium E (WME) (Gibco, Life 
Tecnologies Paesley, Scotland) added with 5% of FBS, 100 UI of penicillin G/mL 
and 100 µg of streptomycin/mL, centrifuged at 1500rpm for 2 minutes and stored 
at 4 °C. To obtain the desired cell concentration, isolation process has been 
performed on 4 different animals. Hepatocytes viability was evaluated by trypan 
blue dye (viability should be grater then 90%) preparing a mix containing 85 l of 
HAM, 5 l of trypan blue and 10 l of isolated hepatocytes. After isolation, 
hepatocytes from different livers were put in the same 50 ml tube, suspended in 
10 mL of Hepatocyte Attachment Medium (Gibco, Life Tecnologies Paesley, 
Scotland), counted in Burker's chamber and then plated  in 12 wells plates 
(360.000 cell/mL), coated with type I collagen (BD Biosciences). Cells were 
incubated at 37°C with 5% of CO2. After 2 hours, medium has been changed with 
FBS-containing WME (WME added with 5% FBS, 100 UI of penicillin G/mL, 100 µg 
of streptomycin/mL, 2mM L-glutamine, 0,1 µM desametasone, 10µg insuline /mL, 
5,5 µg transferrin/mL and 6.7 ng of selenium/mL) and hepatocytes were 
incubated for 4h at 37°C (Fig. 10). 
 
Fig. 10: Optical Microscopy of primary hepatocytes obtained with the protocol 
described above. 
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Primary hepatocytes trasduction with Adenoviruses 
Hepatocytes were stored for about 4 hours in FBS WME, then the 
adenovirus treatments were performed each containing a different shRNA 
sequence (short hairpin RNA) specific for silencing Hdac1, 3, 4, 5, 7 and 
corepressor Smrt. Treatment was carried on four preparations following this 
experimental conditions: 
AdLacZ: transduction control reference. 
AdHdac1: contains Hdac1 specific shRNA. 
AdHdac3: contains Hdac3 specific shRNA. 
AdHdac4: contains Hdac4 specific shRNA. 
AdHdac5: contains Hdac5 specific shRNA. 
AdHdac7: contains Hdac7 specific shRNA. 
AdSmrt: contains Smrt specific shRNA. 
AdHdac4/5/7 co-treatment: contains Hdac4, 5 and 7 specific shRNA. 
For every transduction reaction well, 100 MOI (Molteplicity Of Infection) of 
virus were added. MOI determine the viral particle number available for each 
cell transduction. Solutions containing the viral vectors were stored at -80°C and 
everyone has been characterized by means of a specific viral title expressed as 
PFU (plaque forming units). The following formula was used to calculate the 
exact amount of adenovirus solution that has to be added in each reaction well 
to obtain the correct MOI: 
MOI x n°cells/mL = total PFU needed 
(total PFU needed) / (PFU/mL) = mL adenovirus solution / well 
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24h after trasduction the medium was removed and changed with FBS-
WME without adenoviruses for other 24h. At the end of this period the medium 
was again substituted with FBS-free WME. 
72h after cell seeding, these were lysed with TRIzol® (Life Technologies) 
for mRNA extraction. 
 
ADENOVIRUSES 
 
ADENOVIRUSES PRODUCTION and PRIMARY HEPATOCYTES TREATMENT 
Adenoviruses (Ad) were produced following BLOCK-iT™ Adenoviral RNAi 
Expression System (Life Technologies): 
LR recombination was performed between pENTR/U6 entry construct and 
pAd/BLOCK-It DEST to generate the pAd/BLOCK-It expression construct (Fig. 11). 
 The purified plasmid was digested with Pac I to expose ITRs.  
293A producer cell line was transfected with adenoviral expression clone 
till they showed 80/90% of CPE (cytophatic effect), occurring typically 14 days 
post-infection. Cell-containing medium was collected, transferred in centrifuge 
tubes thus lysed by means of 3 thaw/dethaw cycles, in which cells were freezed 
at -80°C for 30 min and then heated at 37°C for 20 minutes.  
Cell lysates were then centrifuged at 4000 rpm for 12 min at 4°C, the 
supernatant, the crude viral lysate, was collected and the titer of the adenoviral 
stock was determined. Crude viral lysate of each AdHDACs produced was used to 
transduce primary hepatocytes cultures (Fig. 12). 
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Fig. 11: BLOCK-iT™ Adenoviral RNAi Expression System 
 
 
Fig. 12: Crude viral lysate production and transduction of host cells. 
D1 D6 D9 D12 D14: Harvest
293A cells
crude viral lysate of
AdHDAC1, 3, 7
and AdSMRT
Transduction of host cells
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ADENOVIRUSES AMPLIFICATION and PURIFICATION 
 
Adenovirus Titer Amplification 
293A cells were plated in 15 T175 flasks and cultured till 80% of 
confluence. Infection solution was prepared adding 3 ml of crude viral lysate at 
109 title to 72 ml of medium; 5 ml of this solution was diluted with 15 ml of 
medium and added to the cell culture of each flask. When about the 50-60% of 
cells were detached from the flask bottom, observed visually, the flask was 
manually shacked till whole the cells were floating. Cell-containing medium was 
collected and transferred in centrifuge tubes. After a centrifugation at 1000 rpm 
for 5 min at 4°C the supernatant was removed and the pellet was resuspended in 
8ml of sterile PBS. 
Cells then were lysed by means of 4 thaw/dethaw cycles, in which cells 
were freezed at -80°C for 30 min and then heated at 37°C for 20 minutes. The 
lysed cells were then centrifuged at 4000 rpm for 12 min at 4°C and the 
supernatant collected for the purification process. 
Adenovirus Purification 
After amplification Adenoviruses were purified on an ultracentrifuge 
(Beckmann). The first step provides for a 24000 rpm centrifugation in a SW28 
rotor for 4 hours at 4°C on cesium chloride gradient. The full capsides were 
separated from other remnants and can be collected and prepared for the 
second centrifugation  at 24000 rpm in a SW41 rotor O/N at 4°C on cesium 
chloride. 1-2 ml of the central band containing Adenoviruses were collected and 
purified with dialysis process. 
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Adenovirus Dialysis  
Recovered Adenoviruses solutions were inserted in a dialysis membrane 
(Thermo-Pierce) and placed in a 500 ml beaker containing dialysis buffer 
consisting of:  
BSA  
NaCl 
Tris-HCl 1M 
Bidistilled water 
Glycerol 
The membrane was left for 24h in the dialysis solution that has been 
changed every 4 hours. Finally Adenoviruses titer was determined and Ad were 
stored at -80°C. 
 
GENERATION OF LIVER CONDITIONAL KO MICE H7LivKO 
 
Cre-Lox TECHNOLOGY 
Conditional knock-out mice lacking Hdac7 only in the liver were obtained 
by mean of the Cre-Lox technology, which allows to delete a gene between two 
loxP sites by using a Cre enzyme that is able to recognize and catalyze the 
recombination between two specific LoxP sequences. LoxP sites are localized in 
the introns of the gene to be deleted, so that Cre causes the ablation of DNA 
sequence between the LoxP sites. Since a total body Hdac7 knock-out mouse is 
not viable cre is associated at the albumin promoter, so that this enzyme is 
produced only in the liver leading to the hepatic selective deletion of Hdac7 
(Fig. 13). 
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Fig. 13: Cre-Lox technology in the generation of H7LivKO mice 
LoxP sites are inserted between exons 1 and 11 of Hdac7 gene. When albumin 
promoter is active Cre is expressed and HDAC7 gene deleted. 
 
To generate H7LivKO mice we used Alb-Cre mice (Cre+/-) and Hdac7 
LoxP/+ (Hdac7fl/+) heterozygous with a C57BL/6J genetic background obtained 
after crossing mice for 8 generations. Hdac7fl/+ heterozygous were crossed each 
other to generate Hdac7 LoxP/LoxP homozygous mice (Hdac7fl/fl). Hdac7fl/fl 
and Cre+/- were crossed as illustrated below to obtain H7LivKO mice (Hdac7fl/fl; 
Cre+/-). 
 
 
 
HDAC7 LoxP
1111 12 13 142 3 4 5 6 7 8 9 10
Cre-mediated
excision
11 11 12 13 14
HDAC7Floxed
F1 X
50% Hdac7 fl/+; Cre +/-
F2 X
25% Hdac7 fl/fl; Cre +/-
25% Hdac7 fl/fl; Cre -/-
F3 X
50% Hdac7 fl/fl; Cre +/-
50% Hdac7 fl/fl; Cre -/-
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GENOTYPING 
To genotype these mice DNA was extacted from mice tails by NucleoSpin® 
Tissue (Macherey-Nagel) and quantified with Nanodrop (Thermo Scientific). Two 
different reaction mix were prepared to verify the presence of Cre and of LoxP 
on agarose gel (Fig. 14). 
 
Fig. 14: Agarose gel of LoxP and Cre sequences in H7LivKO and Ctrl mice 
495= LoxP; 341= MEH (Microsomal Epoxid Hidrolase, positive control); 411= Cre 
 
PERCENTAGE OF EXCISION by REAL-TIME qPCR 
In order to verify the deletion of Hdac7 gene, Cre excision efficiency was 
evaluated for each mouse. DNA was extacted from mice livers and tails by 
NucleoSpin® Tissue (Macherey-Nagel) and quantified with Nanodrop (Thermo 
Scientific). Liver gene expression was compared to the gene expression in the 
tail, where the gene is not deleted, by Real Time PCR  with iScriptTM One Step 
RT-PCR for Syber (Bio-Rad, Milano, Italia) and 36B4 as housekeeping gene. 
Gene Sequenza 
36B4 Fwd 5’-3’  AGATGCAGCAGATCCGCAT 
Rev 5’-3’  GTTCTTGCCCATCAGCACC 
Hdac7fl/fl Geno-SA 5’-3’  GTTGCAGGGTCAGCAGCGCAGGCTCTG 
Geno-SA 3’-5’  CCAGTGGACGAGCATTCTGGAGAAAGGC 
The oligonucleotides used for real-time PCR were synthesized by Eurofin 
MWG Operon (Ebersberg, Germany). Protocol: 4 min at 95°C; 30 sec at 95°C 
denaturation step; 30 sec at 60°C annealing step; 40 sec at 72°C extension step. 
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ANIMAL STUDIES 
 
HDAC INHIBITORS TREATMENT 
C57BL/6J mice (Charles River Laboratories) were intraperitoneally 
injected every day for 7 days with DMSO as vehicle, SAHA 25 mpk (mg per kilo), 
MS275 10 mpk and MC 1568 6,5 mpk. Livers were collected for total RNA 
extraction and analysis of Cyp7a1 levels. All the compounds were dissolved in 
DMSO and stored at +4°C. Prior to use, the solutions were warmed in a 42°C 
water bath with agitation. Animal studies were conducted strictly following 
regulations of European Community (Directive 2010/63/EU) and local regulations 
for animal care (Decreto Legislativo 4 marzo 2014, n. 26). 
 
Adenovirus infection of C57BL/6J 
C57BL/6J mice (Charles River Laboratories) were divided in 4 groups 
(AdLacz, AdHdac1, AdHdac7, AdSmrt) each including 7 animals; they were first 
anhestesized with ketamin/xylazin. Animal studies were conducted strictly 
following regulations of European Community (attachment IV of Directive 
2010/63/EU) and local regulations for animal care (Decreto Legislativo 4 marzo 
2014, n. 26). 
Virus titer (pfu/ml)/pfu to inject in vivo = ml of Adenovirus per mouse 
ml of Adenovirus per mouse x n° of animals = total amount of Adenoviruses 
 Add physiological solution to Adenoviruses till a final volume calculated as 
100µl x mouse.  
100 µl  containing 6 * 109 pfu of Adenovirus were intrajugular injected to 
each mouse. Mice were sacrificed 5 days after infection. 
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For blood analysis, blood was collected at sacrifice from the heart. Body 
weight was measured before and post infection. Cholesterol levels were 
determined using Plasma Cholesterol kit (Sentinel). Livers were collected for 
total RNA extraction and analysis of HDACs knock down and Cyp7a1 levels. 
 
H7LivKO  
Six week old Hdac7 fl/fl;Cre-/- (CTRL) and six week old Hdac7 fl/fl;Cre+/- 
(H7LivKO) mice were fed for 16 weeks a Western type diet (Harlan), containing 
21% milk derived fats, 34% sucrose and 0,2% cholesterol to increase cholesterol 
levels. Animal studies were conducted strictly following regulations of European 
Community (Directive 2010/63/EU) and local regulations for animal care 
(Decreto Legislativo 4 marzo 2014, n. 26). Animals had free access to food and 
water and the light cycle was from 7:00 A.M. to 7:00 P.M. After 16 weeks mice 
were anesthetize by mean of xylazin and ketamin and sacrificied with carbon 
dioxide (allegato IV della direttiva 2010/63/UE). Total RNA was extracted from 
livers and analyzed via Real-Time qPCR. Plasma, livers and tails were collected 
at sacrifice from individual animals. Feces were collected for 72h 1 week before 
sacrifice. Food consumption and body weight were evaluated. Cholesterol levels 
were determined by the Plasma Cholesterol Kit (Sentinel). Cholesterol 
distribution in plasma lipoprotein fractions was determined by FPLC using a 
Superose 6 column (Amersham, Milano, Italia). One-ml fractions were collected 
and assayed for cholesterol using an enzymatic kit (Sentinel) and triglycerides 
(Sentinel). An agarose electroforetic analysis of lipoproteins was performed on 
plasma samples. Liver slices were stained with E&E staining. 
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LIVER BILE ACID, CHOLESTEROL and TRIGLYCERIDES 
CONTENT 
  
200mg of livers were homogenized in 1mL PBS in Tissue Lyser II (Qiagen®) 
and 2x105 disintegrations per minute of [3H]triolein were used to normalize for 
recovery. Total lipids were extracted by adding 10 mL chloroform/methanol 
(2:1). The organic phase was recovered and dried, and radioactivity was counted 
via liquid scintillation Tri-Carb 2100 TR (Perkin Elmer®). For the determination of 
BA, triglycerides and cholesterol content in liver extracts, samples were diluted 
20-fold with 65 mM phosphate buffer (pH 7.0). BA, triglycerides and cholesterol 
concentrations were measured with enzymatic kits (Sentinel). 
 
RNA EXTRACTION and REAL-TIME qPCR  
 
Total RNA from murine primary hepatocytes, Hepa 1-6 cells and HepG2 
2.2.1 luc and from mouse livers was double extracted with TRIzol Reagent® 
(Invitrogen), purified with commercial kit (Macherey-Nagel, Milano, Italia), and 
quantified with Nanodrop (Thermo Scientific, Wilmington, DE). Specific mRNA 
was amplified and quantitated by real time PCR, using iScriptTM One Step RT-
PCR for Probes (Bio-Rad, Milano, Italia), following the manufacturer’s 
instructions. Primer sequences are available on request. Data were normalized to 
36B4 mRNA and quantitated setting up a standard curve. 
Experiments were performed in triplicate and repeated at least twice with 
different cell preparations. Primers for real-time PCRs were designed by IDT 
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software available on line optimized to work in a one-step protocol (10 min at 
50°C for reverse transcription, 40 cycles of amplifications each consisting of a 
denaturation step at 95° C for 10 s and an annealing/extension step at 60° C for 
30 s). The oligonucleotides used for real-time PCR were synthesized by Eurofin 
MWG Operon (Ebersberg, Germany). 
 
IMMUNOHISTOCHEMISTRY 
 
Liver was fixed with Carnoy solution/Clorophorm, dehydrated, and 
embedded in paraffin, and 8 μm thick sections were subjected to hematoxylin-
and-eosin staining. For immunohistochemistry, liver slices containing 8 μm 
sections were deparaffinized with xylene and rehydrated through graded 
ethanol. Antigen retrieval was performed with HCl 1N for 10 min on ice, 10 min 
at RT and with HCl 2N for 20 min at 37°C. Blocking step was performed 
incubating the slices in 5% BSA in TBS 1X for 2 hours RT. Polyclonal rabbit anti 
HDAC7 antibody (Abcam) was applied at 1:20 concentration in BSA 3% TBS O/N at 
4°C. Slices were subsequently incubated with Alexa Fluor 488 goat anti-rabbit 
IgG (diluted 1:250 in TBS 3% BSA) (Invitrogen) was added as a secondary antibody 
for 1 hour at RT. To stain the nuclei slices were incubated with Hoechst 1:1000 in 
TBS 1X for 30 min RT. Slices were analyzed with a confocal microscope (Nikon 
Eclipse TE2000-S, Radiance 2100, Bio-Rad Laboratories). Image acquisition was 
performed with Laser Sharp software (Bio-Rad Laboratories). 
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LC-MS/MS BASED ASSAY for THE QUANTITATION of 
ENDOGENOUS BILE ACIDS 
 
BA were quantified by means of a commercial kit sold by Biocrates Life 
Sciences ( Innsbruck, Austria) that uses liquid chromatography coupled with mass 
spectrometry as detector. BA were quantified starting from 3 different matrix: 
Feces, Liver, Plasma. All these tissues were collected and treated differently due 
to their heterogeneity. 
 
Feces sample preparation 
Feces were collected from cages, every stool sample came from a single 
animal.  Feces collection lasted 72h, the sample was homogenized and 
lyophilized. About 50mg of this sample were used for BA extraction with about 
1ml of methanol, homogenized in Tissue Lyser II (Qiagen®) and centrifuged. 
500µl of the supernatant were dried under nitrogen and the remnants dissolved 
in 40µl of methanol. A 10µl aliquot was transfered into the kit provided plate. 
 
Liver sample preparation  
About 200 mg of liver were extracted for the quantification of BA with 1ml 
of methanol, homogenized using a Tissue Lyser II (Qiagen®) and centrifuged. 
500µl of the supernatant were dried under nitrogen and the remnants dissolved 
in 40µl of methanol. A 10µl aliquot was transfered into the kit provided plate. 
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Plasma sample preparation 
Plasma samples were collected after whole blood centrifugation. Being 
already in solution plasma didn't need any further treatment and was directly 
transferred into the kit provided plate. 
 
Kit parameters 
LC-MS/MS platform:  ABSciex  API 4000 (ABSciex) 
Ionization mode: Negative 
Chromatographic column: column for Absolute IDQ Bile Acid Kit (BIOCRATES) 
equipped with Security Guard ULTRA Cartridge C18/XB-C18 (Phenomenex) 
Sample preparation: Direct extraction on Biocrates 96 well Kit filter plate, ca. 
1.5 hours 
Sample Volume: 10 µl  
Run time: 11 min/ sample 
IS: 10 isotope labeled internal standard, provided with the kit 
Mobile Phases:  
A. MilliQ water (10mM NH4Ac, 0,015% formic acid) 
B. CAN/MeOH/Water 65/30/5 (10mM NH4Ac, 0,015% formic acid) 
 
STATISTICAL ANALYSIS 
 
Statistical analyses were performed by Student’s t test for the comparison 
of two different experimental groups or one-way ANOVA with the indicated post-
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test for multiple testing comparisons. All statistical analyses were performed 
using GraphPad Prism 5.0 (GraphPad Software, Inc., La Jolla, CA, USA). Data 
were expressed as Mean +/- Standard Deviation; p < 0,05 was considered 
statistically significant. 
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MODULATION of CLASS I HDAC ACTIVITY with SELECTIVE  
HDAC INHIBITORS TOTALLY PREVENTS BA REPRESSION of 
CYP7A1 TRANSCRIPTION in vitro and  INCREASES the 
EXPRESSION of Cyp7a1 in vivo 
 
As previously published by our laboratory, HDACs are key regulators of 
CYP7A1 gene transcription that in response to BA are recruited on the promoter 
of this gene leading to the inhibition of its transcription (Mitro et al., 2007). 
Since, it has been shown that only class I and class II HDACs are involved in the 
regulation of CYP7A1, to go further in the understanding of this regulatory 
mechanism, my first objective was to investigate whether either class I or class 
II of HDACs played a predominant role in the regulation of CYP7A1 expression. 
Therefore, to study the involvement of the specific classes of HDACs in 
the transcriptional regulation of CYP7A1 gene promoter in the native chromatin 
context, I used a stable human hepatoma reporter cell line, HepG2 2.2.1 luc, 
containing the human CYP7A1 promoter upstream of luciferase gene. The 
promoter activity of the luciferase reporter gene construct was studied in 
response both to chenodeoxycolic acid (CDCA) and to three different HDAC-
inhibitors. In particular I used the pan-inhibitor SAHA, that inhibits both class I 
and class II, the class I selective inhibitor MS275 and the class II selective 
inhibitor MC1568 (Fig. 15). 
These data showed that the decreased expression of hCYP7A1 that 
occured after BA treatment was totally prevented in presence of the pan-
inhibitor SAHA. Same results were obtained after treatment with the class I 
selective inhibitor MS275, that moreover greatly increased hCYP7A1 basal level. 
On the other hand the treatment with the class II selective inhibitor MC1568 only 
elicited a partial recovery of CYP7A1 promoter driven transcription. These data 
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highlight the peculiar role of class I HDACs in the regulation of hCYP7A1 gene 
transcription in response to BA. 
 
 
Fig. 15: Class I selective HDAC-i MS275 totally prevents the repressive effect of 
BA on hCYP7A1 expression in HepG2 2.2.1 luc cell line 
Evaluation of hCYP7A1 transcriptional activity by luciferase activity assay in 
HepG2 2.2.1 luc cell line treated O/N with DMSO 0,1% as control, CDCA 25 µM and 
the three HDAC inhibitors, SAHA 2.5 µM, MS275 5µM or MC1568 5µM, alone and in 
combination with CDCA 25 µM. Data are expressed as percentage of luciferase 
activity compared to control (CTRL) and they are normalized on the total protein 
amount quantified by BCA assay. Representative data shown are the averages of 
six replicate assays in three experiments. Error bars indicate standard deviation 
from the mean. ANOVA statistical analysis was performed; *** indicates statistical 
significance with p<0.001. 
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To investigate the contribution of class I and II HDACs in vivo, I 
administered the same HDAC inhibitors by IP injection on C57BL/6J mice. The 
treatment with the class I selective HDAC-inhibitor MS275 showed a statistically 
significant increase of liver Cyp7a1 gene expression also in vivo, confirming the 
in vitro data (Fig. 16), nonetheless I observed a mild induction of Cyp7a1 gene 
expression, albeit not statistically significant, even after SAHA and MC1568 
administration. 
 
 
Fig. 16: Class I selective HDAC-i MS275 increases mCyp7a1 expression in vivo  
mCyp7a1 mRNA expression in C57BL/6J mice treated every day for 7 days with 
DMSO as vehicle, SAHA 25 mpk, MS275 10 mpk and MC1568 6,5 mpk. Liver samples 
were analyzed by real-time Q-PCR to determine mRNA levels. Data are expressed 
as mean ± SD. ANOVA statistical analysis was performed; * indicates statistical 
significance with p<0.05. 
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SILENCING of HDAC1, HDAC3 and HDAC7 INCREASES 
hCYP7A1 TRANSCRIPTION in HepG2 2.2.1 Luc  
 
To corroborate the results obtained with HDAC inhibitors and to pinpoint 
the role of specific HDACs involved in the regulatory mechanism of CYP7A1 gene 
transcription, I used an RNAi approach. I knocked-down HDACs using siRNA 
oligonucleotides silencing HDAC1, 3 belonging to Class I, and HDAC 7 belonging 
to Class II in HepG2 2.2.1 luc cell line.  
After confirming their efficiency to silence their target gene expression 
(Fig. 17a), I measured the promoter activity of the luciferase reporter gene 
construct both in presence and in absence of BA. 
As shown in Fig. 17b, I observed that HDAC1 silencing highly increased 
hCYP7A1 transcription and it totally prevented BA repressive effect on the 
expression of this gene, highlighting an important role of HDAC1 in the 
regulation of hCYP7A1 gene and pointing out the results previously obtained with 
class selective HDAC inhibitors. HDAC3 and HDAC7 silencing slightly increate 
hCYP7A1 expression as an evidence of their involvement in the regulatory 
pathway of hCYP7A1 transcription. Moreover, HDAC3 knock-down showed only a 
not statistically significant trend of prevention of BA effect while HDAC7 knock-
down elicited a partial but significant recovery of hCYP7A1 after BA treatment 
suggesting its peculiar role in this pathway. 
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Fig. 17: 
a) HDACs silencing by siRNA oligonucleotides in HepG2 2.2.1 luc cell line 
Q-PCR determination of mRNA expression of HDAC1, HDAC3 and HDAC7 in HepG2 
2.2.1 luc cell line after treatment with the respective siRNA sequences compared 
to control scramble (CTRLsiRNA); HDAC3 and HDAC7 silencing is higher than 85% 
and HDAC1 silencing is 60%. Data are expressed as mean ± SD. Student’s t test 
statistical analysis was performed; ** indicates statistical significance with p<0.01; 
*** indicates statistical significance with p<0.001. 
 
b) hCYP7A1 promoter activity in HepG2 2.2.1 luc cell line treated with siRNA 
oligonucleotides vs HDAC 1, 3 and 7 
Evaluation of hCYP7A1 transcriptional activity by luciferase activity assay in 
HepG2 2.2.1 luc cell line treated with HDAC1, HDAC3 and HDAC7 siRNA sequences 
100nM alone or together with CDCA 25 µM, compared to control scramble 
(CTRLsiRNA). Data are expressed as mean ± SD. ANOVA statistical analysis was 
performed; * indicates statistical significance with p<0.05; ** indicates statistical 
significance with p<0.01; *** indicates statistical significance with p<0.001. 
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Hdac1, 7 and Smrt SILENCING SIGNIFICANTLY INCREASES 
Cyp7a1 EXPRESSION in MURINE PRIMARY HEPATOCYTES 
 
To unravel the role of specific HDACs and corepressors in vivo and to study 
their contribution in Cyp7a1 regulation, I planned to perform silencing 
experiments in vivo by using Adenoviral vectors expressing shRNA. 
To this end I first identified murine siRNA oligonucleotides silencing Hdac 
1, 3, 7 and the corepressor Smrt by testing them in a murine model of 
hepatoma, Hepa 1-6 cell line. Three different siRNA sequences for each gene 
were analyzed and I selected the ones able to produce the best silencing (Fig. 
18), which were used as templates to design shRNA against Hdacs and the 
corepressor Smrt to be used in vivo in adenoviral vectors. 
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 Fig. 18: HDACs gene silencing in murine Hepa 1-6 cell line 
Relative expression of genes coding HDACs measured by Real-Time PCR in Hepa 1-
6 cells total RNA. Cells were transfected with transfection reagent (CTRLsiRNA) or 
siRNA 30nM/100Nm. RNA was extracted 48h after transfection. I obtained 80-90% 
silencing of Hdac7 gene and a 50-70% silencing of Hdac1, Hdac3 and Smrt/N-CoR 
genes. Data are expressed as mean ± SD and are normalized with 36b4 as 
reference gene. Student’s t test statistical analysis was performed; * indicates 
statistical significance with p<0.05; ** indicates statistical significance with 
p<0.01; *** indicates statistical significance with p<0.001. 
 
Based on these siRNA oligonuceotides I designed shRNA sequences 
silencing murine Hdac1, Hdac3, Hdac7 and Smrt and I cloned them in 
adenovectors producing the respective Adenoviruses (Ad). Furthermore, since in 
literature it has been reported that cells can compensate for the lack of Hdac 7 
increasing the amount of Hdac 4 and 5 (other two members of class II Hdacs) 
(Mihaylova et al., 2011), I also produced Ad against Hdac 4 and 5. To evaluate 
their silencing efficiency I treated murine hepatocytes cultures with the Ad, 
each containing a shRNA specific for the respective target gene silencing. I used 
100 MOI (Molteplicity of Infection) of virus, that means the number of viral 
particles available for one cell trunsduction. Ad allows shRna to enter 
hepatocytes cytoplasm and to recognize a complementary RNA leading to its 
degradation. After transduction with adenoviral sh RNA, I analyzed Hdac1, 3, 4, 
5, 7 and Smrt gene expression by real time qPCR observing that the transduction 
significantly silenced Hdac1, 4, 5, 7 e Smrt genes while Ad containing shRNA 
targeting Hdac3 was not able to silence its target (Fig. 19). 
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Fig 19: Hdac1, Hdac4, Hdac5, Hdac7 and Smrt silencing on murine primary 
hepatocytes 
Relative expression of genes coding HDACs measured by Real-Time PCR on murine 
primary hepatocytes total RNA. Cells were transducted with the respective Ad 
(100 MOI) and compared to control AdLacz. RNA was extracted 72h after 
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transduction. AdHdac1, AdHdac4, AdHdac5, AdHdac7 e AdSmrt reduce the 
expression of their relative target genes respectively by 62%, 53%, 70%, 83% and 
43%. Co-trasduction of AdHdac 4, 5 e 7 is able to silence Hdac4 by 37%,  Hdac5 by 
62% and Hdac7 by 66%. Data are expressed as mean ± SD and are normalized on 
36b4 as reference gene. Student’s t test and ANOVA statistical analysis were 
performed; * indicates statistical significance with p<0.05; ** indicates statistical 
significance with p<0.01; *** indicates statistical significance with p<0.001. 
 
Having confirmed that these Ad expressing shRNAs were able to repress 
their target gene expression, I investigated the contribution of the silencing of 
every specific Hdac or Smrt in the modulation of Cyp7a1 gene expression in 
primary murine hepatocytes by real time qPCR in these cells after Ad treatment. 
Hdac1, 7 and Smrt silencing significantly increased Cyp7a1 expression. 
Furthermore, AdHdac4 and AdHdac5 raised Cyp7a1 transcription but the co-
silencing of AdHdac4 and AdHdac5 with AdHdac7 had neither additive nor 
synergistic effect, suggesting that Hdac7 silencing is sufficient to induce Cyp7a1 
expression (Fig. 20). Since AdHdac3 was not able to reduce Hdac3 expression, 
the contribution of Hdac3 deletion in Cyp7a1 regulation could not be 
investigated. 
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Fig. 20: Cyp7a1 gene expression levels in murine primary hepatocytes treated 
with AdHDACs and AdSmrt: 
Q-PCR determination of Cyp7a1 mRNA expression on murine primary hepatocytes. 
Cells were transducted with the respective Ad (100 MOI) and compared to control 
AdLacz. RNA was extracted 72h after transduction. Cyp7a1 mRNA levels are 7 fold 
increased by AdHdac1 compared to the empty vector AdLacZ, 8 fold by AdSmrt 
and 21 fold by AdHdac7 alone or in co-treatment with AdHdac 4, and 5. Data are 
expressed as mean ± SD and are normalized on 36b4 as reference gene. ANOVA 
statistical analysis was performed with Dunnett’s Multiple Comparison post test vs 
AdLacZ; * indicates statistical significance with p<0.05; ** indicates statistical 
significance with p<0.01. 
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Hdac7 and Smrt SILENCING SIGNIFICANTLY INCREASES 
Cyp7a1 EXPRESSION in vivo 
To investigate the acute effect of silencing Hdacs and Smrt, I amplified 
and purified the Ad used in the experiment described above to proceed with the 
in vivo treatment. C57BL/6J mice were divided in 4 groups, one for each 
treatment, and injected in the jugular vein with 6*109 pfu of AdLacz, AdHdac1, 
AdHdac7 and AdSmrt.  
Body weight of mice at the beginning (B.I.) and at the end (A.I.) of the Ad 
infection (at sacrifice) did not yield any difference neither among the groups of 
treatment nor between B.I. and A.I. (Fig. 21), meaning that Ad did not affect 
health of infected mice. 
 
Fig. 21: Mice body weight 
Mice body weight before (B.I.) and after (A.I.) infection with Ad in C57BL/6J mice. 
Data are expressed as mean ± SD. TWO WAY ANOVA statistical analysis was 
performed and no statistically significant difference was observed. 
Real Time PCR analysis of total RNA from liver extracts of mice infected 
with Ad revealed that AdHdac1 (Fig. 22A) was ineffective in silencing its target 
gene, whose expression did not significantly differ from control AdLacz. AdHdac7 
and AdSmrt infections, instead, efficiently reduced Hdac7 and Smrt expression 
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respectively (Fig. 22B, C). Therefore, I measured the contribution of these 
knock-down on Cyp7a1 expression and I found that AdHdac1, consistent with its 
inability in silencing its target gene, did not affect the expression of the gene, 
while AdHdac7 and AdSmrt significantly increased Cyp7a1 mRNA levels (Fig. 23), 
confirming their important role in the regulation of BA metabolism also in vivo.  
 
Fig. 22: Hdac1, Hdac7 and Smrt silencing in C57BL/6J mice 
Relative expression of genes coding Hdac1, Hdac7 and Smrt measured by Real-
Time PCR. Mice livers collected 5 days after intra-jugular injection with the 
respective Ad (6*109 pfu) were compared to to control AdLacz. Data are expressed 
as mean ± SD and are normalized on 36b4 as reference gene. Student’s t test 
statistical analysis was performed; * indicates statistical significance with p<0.05; 
** indicates statistical significance with p<0.01. 
 
Fig. 23: Cyp7a1 gene expression levels in C57BL/6J mice treated with 
AdHDACs and AdSmrt 
Q-PCR determination of Cyp7a1 mRNA expression on liver extracts of mice 
infected with AdHDACs and AdSmrt. Mice livers collected 5 days after intra-jugular 
injection with the respective Ad (6*109 pfu) were compared to control AdLacz. 
Data are expressed as mean ± SD and are normalized on 36b4 as reference gene. 
Student’s t test statistical analysis was performed; * indicates statistical 
significance with p<0.05; *** indicates statistical significance with p<0.001. 
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Next, I measured total plasma cholesterol in these mice and, as expected, 
I did not observe differences among the groups, most likely because a 5 days 
treatment was not sufficient to elicit significant changes in cholesterol 
metabolism (Fig. 24).  
  
Fig. 24: Plasma 
Cholesterol levels 
after Ad treatments 
Plasma Cholesterol 
levels after AdHdacs 
and AdSmrt treatment 
at sacrifice reveale any 
significant change 
among the groups. Data 
are expressed as mean 
± SD. ANOVA statistical 
analysis was 
performed. 
 
HDAC7 DELETION INDUCE PHENOTYPICAL IMPROVEMENT 
ON CHOLESTEROL and LIPOPROTEIN PROFILE of H7LivKO 
mice 
 
Previous investigations performed in our laboratory demonstrated that 
HDAC7 shuttles from the cytoplasm to the nucleus in hepatic cells treated with 
BA, and subsequently is recruited to CYP7A1 promoter as part of the repressive 
complex. This suggests a central role of HDAC7 in the inhibitory feedback of 
CYP7A1 mediated by BA and consequently on cholesterol homeostasis (Mitro et 
al., 2007). Therefore, since it was shown that the total body knock-out is not 
viable, to investigate the role of HDAC7 in vivo I generated HDAC7 liver-specific 
knock-out mice (H7LivKO) with the Cre/Lox technology. Mice were challenged 
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with Western Diet, a diet enriched in cholesterol with the aim to emphasize the 
possible effect of Hdac7 deletion on cholesterol and BA metabolism. 
Actual deletion of Hdac7 was assessed by real time qPCR of liver genomic 
DNA vs non hepatic genomic DNA. H7LivKO mice with excision percentage lower 
than 60% were excluded from the study (Fig. 25). Moreover, Hdac7 deletion was 
confirmed by immunofluorescence analysis observed with confocal microscopy 
(Fig. 26). 
 
Fig. 25: Hdac7 percentage of excision 
Excision efficiency by Cre recombinase on LoxP sites 
insered into Hdac7 gene in the liver was evaluated 
comparing liver expression to tail expression, in 
which the gene is not deleted. 
 
 
Fig. 26: Hdac7 deletion in H7LivKO 
Immunofluorescence analysis of Hdac7 on liver slices of H7LivKO and wild type 
mice on western diet. 
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REDUCED BODY WEIGHT in H7LivKO on Western Diet 
Body weight analysis showed 12% statistically significant reduction in 
H7LivKO mice compared to wild type mice (Fig. 27A), despite the equal food 
consumption (Fig. 27B), suggesting a possible role of HDAC7 on lipid metabolism. 
 
 
Fig. 27: Body weight reduction in H7LivKO mice fed WD: 
Body weight (A) and food consumption (B) in H7LivKO mice compared to wild type 
mice after 16 weeks on Western diet. Data are expressed as mean ± SD. Student’s 
t test statistical analysis was performed; * indicates statistical significance with 
p<0.05. 
 
REDUCED LDL-CHOLESTEROL in H7LivKO on Western Diet 
Mice on Western diet (WD) showed total plasma cholesterol levels 
significantly higher than mice on Chow diet (CD); moreover, I observed a 
statistically significant decrease of total plasma cholesterol, equal to 11%, in 
H7LivKO mice compared to wild type (wt) mice (Fig 28A).  
In light of this evidence, I decided to better characterize this difference 
by performing Fast Protein Liquid Chromatography (FPLC) to analyze cholesterol 
levels in the different lipoprotein fractions. The FPLC analysis revealead a 
reduction of LDL-Cholesterol in H7LivKO mice compared to the respective 
controls (Fig. 28B).   
Food consumption
CTRL H7LivKO
0
1
2
3
(g
/m
o
u
se
/d
a
y)
CTRL H7LivKO
0
10
20
30
40
*
Body weight
(g
)
-12%
A B
Results 
     
 
72 
 
 
 
Fig. 28: Plasma cholesterol analysis on H7LivKO mice fed WD 
A) Total plasma cholesterol levels of control mice on WD are significantly higher 
than mice on CD. 11% decrease of total plasma cholesterol is observed in mice 
lacking HDAC7 in the liver compared to control on WD. Data are expressed as 
mean ± SD. Student’s t test statistical analysis was performed; * indicates 
statistical significance with p<0.05.  
B) Fast Protein Liquid Chromatography revealed a reduced amount in LDL-
cholesterol in H7LivKO mice. 
 
REDUCED LIVER LIPID ACCUMULATION and LIVER CHOLESTEROL in H7LivKO 
on Western Diet 
We next analyzed the hepatic lipid content in wt and H7LivKI mice. 
Histological analysis by hematoxylin and eosin staining on liver slices highlighted 
lower lipid accumulation in H7LivKO compared to wt mice (Fig. 29). 
 
Fig. 29: Liver lipid 
accumulation  
8 µm liver sections 
with hematoxylin 
and eosin staining 
of H7LivKO (right) 
and wyld type mice 
(left) on WD. 
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I extracted and quantified triglyceride and cholesterol levels, typical 
components of lipid droplets observed in hepatic steatosis. Surprisingly, liver 
triglycerides were reduced in H7LivKO though the difference did not reach 
statistical significance (Fig. 30A). On the other hand, I observed a statistically 
significant reduction of hepatic cholesterol levels in H7LivKO mice compared to 
controls (Fig. 30B). 
 
 
Fig. 30: Hepatic lipid analysis 
A) Liver Triglycerides quantification after lipid extraction by methanol:chloroform 
using 3H-triolein as internal standard. Data are expressed as mean ± SD. 
B) Liver Cholesterol quantification after lipid extraction by methanol:chloroform 
using 3H-triolein as internal standard. Data are expressed as mean ± SD. Student’s 
t test statistical analysis was performed; * indicates statistical significance with 
p<0.05. 
 
INCREASED Liver BILE ACIDS and Cyp7A1 in H7LivKO on Western Diet 
Consistent with hepatic cholesterol decrease in H7LivKO mice, I also 
observed increased liver BA in knock out vs wt mice. Consistent with these 
results, Cyp7a1 expression was higher in H7LivKO vs wt mice (Fig. 31A e B), 
suggesting that upregulation of the rate-limiting enzyme in BA synthesis resulted 
in increased BA production. 
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Fig. 31: Increased Liver BILE ACIDS and Cyp7A1 in H7LivKO on Western Diet 
A) Liver BA quantification after lipid extraction by methanol:chloroform using 3H-
triolein as internal standard. Data are expressed as mean ± SD. Student’s t test 
statistical analysis was performed; * indicates statistical significance with p<0.05. 
B) Q-PCR determination of Cyp7a1 mRNA expression of liver extracts. Data are 
expressed as mean ± SD and are normalized on 36b4 as housekeeping gene. 
Student’s t test statistical analysis was performed; * indicates statistical 
significance with p<0.05. 
 
INCREASED LIVER, PLASMA and FECAL BA in H7LivKO on Western Diet 
To better define the impact of Hdac7 ablation on BA metabolism, I 
performed a more detailed analysis of BA by LC-MS/MS for the quantitation of 
endogenous BA in plasma, liver and feces. Unconjugated BA were significantly 
increased in plasma of H7LivKO mice compared to wt mice (Fig. 32 A). The 
analysis of hepatic BA showed increased muricholic acids (MCA), α-MCA and β-
MCA and ursodeoxycholic acid (UDCA), three hydrophilic BA that are antagonists 
of the BA nuclear receptor FXR (Fig. 32 B). With the exception of cholic acid 
(CA), lithocholic acid (LCA) and UDCA, the content of the most Almost all the 
most abundant fecal BA, an index of increased BA biosynthesis, was higher in 
H7LivKO mice (Fig. 32 C). 
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Fig. 32: LC-MS/MS based assay on plasma, liver and feces 
BA quantitation of plasma and liver and feces extracts. Data are expressed as 
mean ± SD. Student’s t test statistical analysis was performed; * indicates 
statistical significance with p<0.05; ** indicates statistical significance with 
p<0.01. 
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H7LivKO SHOW DIFFERENT HDL-CHOLESTEROL PROFILE, RICHER in 
SMALLER HDL 
In depth analysis of lipoprotein subfractions brought up to our attention a 
different population of HDLs. Since FPLC is an exclusion chromatography 
technique, the size of molecules eluting in the late fractions, such as the ones 
displayed in the blue circle of Fig. 33, should be smaller. Therefore, I 
hypothesized that it might be a smaller population of HDL that is present only in 
H7LivKO mice. 
To better investigate this aspect, agarose electroforesis analysis was 
performed. As shown in Fig. 34, plasma samples from control mice were more 
electropositive and enriched in alpha HDL, containing more cholesterol. On the 
other hand, plasma samples from H7LivKO mice migrated farther than controls, 
suggesting that they contained smaller HDLs, probably resembling lipid poor pre-
beta HDLs. 
 
 
Fig. 33: Fast Protein Liquid Chromatography revealed a smaller population of 
HDL-cholesterol in H7LivKO mice 
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Fig. 34: Agarose electroforesis analysis of plasma lipoproteins 
Ab anti ApoA-I was used for the detection of HDLs.  
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This study elucidates some peculiar aspects of the epigenetic 
transcriptional regulation of CYP7A1, the rate-limiting enzyme for cholesterol 
catabolism, deepening the important involvement of HDACs and corepressors in 
this pathway. Several epidemiological studies have well established the 
correlation between hypercholesterolemia and atherosclerosis and 
cardiovascular disease risk. Great attention is turned to the discovery of new 
pharmacological approaches aimed at reducing hypercholesterolemia to 
overcome side effects of the drugs nowadays available and the poor response 
that some patients develop towards these drugs. In this perspective, a deeper 
understanding of the genetic and molecular mechanisms involved in the 
pathophysiological regulation of cholesterol homeostasis is fundamental.  
Quantitatively the most important route of cholesterol disposal in 
mammals is BA biosynthesis (Chiang, 2002). This biosynthetic pathway represents 
the final step of reverse cholesterol transport; in fact, excess of cholesterol 
transported to the liver is catabolized to BA, which play an essential role in 
maintaining cholesterol homeostasis. CYP7A1 is an enzyme expressed only in the 
liver that represents the major check-point of BA biosynthesis and its impact on 
cholesterol homeostasis has been fully demonstrated. The homozygous deletion 
mutation in CYP7A1 locus in human patients, leading to the loss of the active site 
and enzyme function, causes hypercholesterolemia with high levels of LDL 
cholesterol (Pullinger et al., 2002). Moreover, Cyp7a1-tg mice show increased 
hepatic cholesterol catabolism and increased BA pool size, improving high-fat 
diet (HFD)–induced obesity, fatty liver and insulin resistance (Li et al., 2010a). In 
light of this critical role in the maintenance of cholesterol homeostasis, in the 
last decades many studies have been conducted to elucidate its regulatory 
mechanisms. Expression of CYP7A1 gene is feedback inhibited by BA that act on 
their nuclear receptor FXR that in the liver induces the expression of SHP 
(Goodwin et al., 2000, Lu et al., 2000c) and in the intestine the release of FGF 
15/19 (Inagaki et al., 2005), both leading to CYP7A1 inhibition.  
As previously published by our laboratory, BA also repress CYP7A1 gene 
transcription via an FXR-independent pathway, chronologically preceding the 
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FXR-dependent mechanism. BA induce the dissociation of the coactivators PGC-
1α and CBP from HNF-4α, a master regulator of CYP7A1 (De Fabiani et al., 2003) 
and simultaneously induce the recruitment of transcriptional corepressors such 
as NcoR and SMRT, which create a repressive complex on CYP7A1 promoter 
together with HDAC1, 3 and 7 (Mitro et al., 2007). These data highlighted 
epigenetic regulation of cholesterol homeostasis. Epigenetic modifications of 
chromatin induced by HDACs activity modulate gene transcription, impairing 
transcriptional activators accessibility to DNA (López-Rodas et al., 1993b, 
Grunstein, 1997a) and are associated to several pathological conditions, such as 
cancer (Miremadi et al., 2007), insulin resistance and obesity (Xiang et al., 2004, 
Gray and Ekström, 2001). In recent years a growing number of studies pointed 
out the contribution of HDACs in the modulation of lipid (Galmozzi et al., 2013, 
Knutson et al., 2008, Sun et al., 2011) and BA metabolism and on the regulation 
of CYP7A1 (Kemper et al., 2004, Ponugoti et al., 2007). In addition, previous 
studies from our laboratory showed that HDAC inhibitors (HDAC-i) stimulate 
CYP7A1 expression in vitro and in vivo by preventing the negative feedback 
exerted by BA, consequently decreasing serum cholesterol in mice (Mitro et al., 
2007). Therefore, although the involvement of these enzymes in the regulation 
of these processes has been demonstrated, several questions remain unsolved. It 
is still unclear which class of HDACs is mainly involved, what is the contribution 
of specific HDACs and corepressors in the regulation of CYP7A1 gene expression 
and ultimately their impact on BA and cholesterol metabolism.  
To elucidate this issues, first of all, in this study I examined the effects of 
class-selective HDAC inhibitors on the promoter activity of hCYP7A1 in vitro. The 
data obtained suggest a major involvement of class I HDACs in the negative 
regulation of hCYP7A1, since class I selective HDAC inhibitor MS275 was able to 
totally prevent the BA-induced repressive effect on hCYP7A1 promoter, while the 
class II HDAC inhibitor MC1568 yielded only a partial, although significant, 
recovery of gene transcription. The apparently lower contribution of class II 
HDACs might be ascribed, on one hand, to the minimal histone deacetylase 
activity of class IIa HDACs, the subclass involved in this regulation, due to a swap 
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of a key tyrosine residue in the catalytic domain with a histidine (Lahm et al. 
2004); in fact, they mainly act as scaffold molecules to recruit class I HDACs 
(Nebbioso et al., 2009), thence the inhibition of their deacetylase activity does 
not impair their actual function. On the other hand, MC1568 has been well 
described as inhibitor of HDAC4 and HDAC5 (Nebbioso et al., 2009, Scognamiglio 
et al., 2008), but the role on HDAC7, the most involved in CYP7A1 regulation 
among class IIa HDACs, has not been clarified. Therefore, this might explain the 
only partial recovery of gene expression that we observe after class II selective 
MC1568 treatment.  
Moreover, the RNAi approach in the human hepatoma reporter cell line, 
HepG2 2.2.1 luc, allowed to investigate the contribution of HDAC1, HDAC3 and 
HDAC7, identified by Mitro et al. as main constituents of the repressive complex 
formed on hCYP7A1 promoter upon BA treatment (Mitro et al., 2007). Although 
the silencing of these HDACs was able to significantly increase the basal level of 
hCYP7A1, pointing out their relevance in the regulatory mechanism of this gene, 
only HDAC1 and HDAC7 knock-down prevented the BA-induced inhibition of 
hCYP7A1 transcription, highlighting their peculiar role in this pathway. The 
stronger effect of HDAC1 deletion might be partially due to the loss of 
interaction of HDAC1 with SHP that weaken SHP repression on CYP7A1 gene 
transcription as well; in fact, it has been demonstrated that induction of SHP 
plays its repressive effect by recruiting Swi/Snf-Brm chromatin remodeling 
complex, which also contains an mSin3A/HDAC-1, to hCYP7A1 promoter (Kemper 
et al., 2004). 
In light of the possible differences between human and mouse regulation 
of cholesterol catabolism, in this study I also pinpointed the role of specific 
HDACs and corepressors firstly in vitro on murine primary hepatocytes and then 
in vivo on C57BL/6J mice. In the in vitro study I knocked-down Hdac1, Hdac3, 
Hdac7 and Smrt. I also knocked down Hdac4 and Hdac5, since it was previously 
described their possible compensatory role in the absence of Hdac7 (Mihaylova et 
al., 2011). Our results underscore the major contribution of Hdac1, Hdac7 and 
Smrt in the repression of Cyp7a1 mRNA levels. These evidences suggest HDAC7, 
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HDAC1 and SMRT as essential actors in the formation of the repressive complex 
acting on Cyp7a1 promoter, indicating that their recruitment is critical to the 
feedback inhibition of Cyp7a1 gene expression induced by BA. 
The effects observed in vitro on murine primary hepatocytes were also 
confirmed in vivo in C57BL/6J mice, where AdHdac7 and AdSmrt significantly 
increase Cyp7a1 mRNA levels, thus confirming their important role in the 
regulation of BA metabolism in vivo as well. However, AdHdac1 was ineffective in 
silencing its target gene in vivo, therefore further studies will be necessary to 
assess its contribution in the regulation of Cyp7a1 in vivo. In spite of the 
elevated expression of Cyp7a1 gene upon administration of AdHdac7 and AdSmrt, 
no changes of plasma cholesterol levels were observed. This apparent 
discrepancy is actually ascribable to the adenoviral infection protocol. To avoid 
the onset of inflammatory response in the liver a single dose of Ad was injected 
to each mouse and after 5 days mice were sacrificed. Hence, only the acute 
effect of Hdac7 and Smrt deletion on Cyp7a1 expression could be observed 
whereas it was not possible to detect changes of plasma cholesterol levels, as 
they would have need longer time and multiple injections. 
Both the in vitro and the in vivo evidences obtained after silencing, 
highlighted the role of the corepressor Smrt in the regulation of Cyp7a1 gene 
expression. It has been well established, in fact, that NCoR and Smrt recruit 
HDACs and they repress gene transcription by interacting with class I and class II 
HDACs (Kao et al., 2000, Huang et al., 2000). It has been demonstrated that Smrt 
contains a histone interaction domain (HID) and a deacetylase activation domain 
(DAD) that binds and activates HDAC3, promoting the recruitment of repressive 
complex on target gene (Yu et al., 2003). Furthermore, it has been demonstrated 
that corepressors SMRT/N-CoR and mSin3A associate with Hdac7 in yeast and in 
mammalian cells, suggesting association of multiple repression complexes (Kao 
et al., 2000). In line with these evidences, this study suggests a peculiar role of 
the corepressor Smrt that, together with Hdac7 translocating in the nucleus after 
BA administration, might function as a platform in the formation of the 
repressive complex on Cyp7a1 promoter. 
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These evidences together with previous results published by our laboratory 
showing that HDAC7 shuttles from cytoplasm to nucleus in response to BA and 
represses CYP7A1 transcription (Mitro et al., 2007), suggest a key role of HDAC7 
in cholesterol and BA metabolism. Therefore, to investigate more extensively the 
contribution of Hdac7 in the regulation of  Cyp7a1 and its implication in 
cholesterol homeostasis in vivo, I used liver specific Hdac7 conditional knock-out 
mice (H7LivKO). A previous study by Chang and coworkers demonstrated that 
Hdac7 is expressed in the vascular endothelium during early embryogenesis and 
played a crucial role in angiogenesis since it represses matrix metalloproteinase 
(MMP) 10 expression that degrades the extracellular matrix and therefore it 
maintains vascular integrity. In HDAC7 knock-out mice, the lack of this inhibition 
causes loss of endothelial cells adhesion, vascular dilation and rupture resulting 
in embryonic lethality by E11 (Chang et al., 2006). Therefore, to overcome the 
embryonic lethality, I generated a liver specific knock-out mouse, lacking Hdac7 
only in the liver. H7LivKO mice were fed Western diet, a diet enriched in 
cholesterol, to increase the low basal level of LDL cholesterol of wt mice and to 
emphasize the potential effect of Hdac7 loss on BA and cholesterol metabolism. 
The potential role of the hepatic Hdac7 in the regulation of Cyp7a1 gene and the 
impact of its ablation on BA and cholesterol homeostasis in vivo has not been 
investigated previously. This study demonstrated that Hdac7 is deeply involved in 
the molecular regulatory pathway of Cyp7a1 gene expression thus affecting 
cholesterol metabolism and lipoprotein profile. Hdac7 ablation significantly 
increased Cyp7a1 transcription leading to higher content of BA in the liver and in 
plasma. Of note, fecal excretion of major BA, an index of increased BA 
biosynthesis, was higher in H7LivKO mice on Western diet and is likely to explain 
the reduction of liver and plasma cholesterol compared to control mice on 
Western diet. The importance of bile acid homeostasis in the resistance of High 
Fat Diet (HFD)-induced obesity and of hyperlipidemia in mice overexpressing 
Cyp7a1 has been previously well described (Li et al., 2010b). In accordance to 
the evidences showed by Li and coworkers, our study reveals that the induced 
Cyp7a1 expression by the ablation of Hdac7 and the consequent increased BA 
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biosynthesis result in improvement of cholesterol and lipid homeostasis and in 
lipoprotein profile. Despite similar food consumption, H7LivKO mice showed 12% 
reduction of body weight compared to control. This might be a consequence of 
the higher circulating BA, which activate TGR5, the membrane BA receptor 
localized in brown adipose tissue, and increase energy expenditure via 
deiodinase 2 (D2) activation that causes increase of 3,5,3′-tri-iodothyronine (T3) 
and consequently uncoupled protein 1 (UCP1) induction, a well known activator 
of non-shivering thermogenesis (Watanabe et al., 2006); consistent with this 
evidence the increased pool of BA observed in Cyp7a1-tg mice induce fatty acid 
oxidation genes in brown adipose tissue (Li et al., 2010b). Furthermore, H7LivKO 
mice were protected against fatty liver induced by Western diet. The 
morphological evidence was supported by the significant decrease of hepatic 
cholesterol of Western diet-H7LivKO mice, a main component of lipid droplets in 
hepatic steatosis, even though the total hepatic triglycerides content displayed 
only a mild but not significant reduction. It is possible that reduced hepatic 
triglycerides content could be emphasized with a targeted analysis of single fatty 
acids.  
A further evidence of phenotipical improvement of liver in H7LivKO mice 
pointed out by this study was the increased levels of hydrophilic BA in the liver, 
such as α-MCA, β-MCA, ω-MCA and UDCA. Several publications underscore the 
association between hydrophobic BA and liver damage; a more hydrophobic BA 
pool was observed in TGR5 KO mice leading to liver injury (Péan et al., 2013); in 
addition, mice fed with a lithocholic acid–enriched diet exhibit a hydrophobic 
bile composition and bile duct obstruction leading to destructive cholangitis with 
bile infarcts (Fickert et al., 2006). 
Another important evidence highlighted by this study was the reduction of 
LDL-cholesterol in H7LivKO mice fed Western diet. Interestingly, an important 
change also occured in HDL cholesterol. FPLC and agarose electroforesis analysis 
suggest the presence of smaller and less rich in cholesterol HDL poarticles that 
might resemble pre-beta HDL in H7LivKO mice. Since HDLs are major cholesterol 
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carriers in mice, this evidence probably has a major impact on cholesterol 
profile. 
In fact, nascent or pre-beta HDL are a subset of HDL particles poor in 
lipids that are critical in collecting cholesterol from peripheral tissues as the first 
step in reverse cholesterol transport (Barter and Rye, 1996). They function as 
cholesterol acceptors from either cells or apoB-containing lipoproteins, by the 
lecithin:cholesterol acyltransferase (LCAT)-mediated esterification of cholesterol 
becoming mature, lipid-rich, and spherical HDL alpha (von Eckardstein et al., 
2001). The higher presence of pre-beta HDL and the lower alpha HDL content in 
H7LivKO mice fed Western diet, thus might suggest a lower cholesterol 
deposition in peripheral tissues due to higher capacity to remove cholesterol 
from peripheral cells.  
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This study elucidated the importance of specific HDACs and corepressors 
in the regulatory machinery underlying CYP7A1 expression, highlighting HDAC1, 
HDAC7 and SMRT as important players in this pathway. Moreover, it suggests 
HDAC7 as a crucial actor of this pathway, affecting cholesterol and lipid profile 
in vivo. The results obtained with the investigations performed during my 
doctorate training represent a step forward contributing to shed light on the 
mechanisms of CYP7A1 regulation and their impact in lipid homeostasis. It 
remains to be elucidated the mechanism underlying the phenotypical 
improvement caused by the ablation of Hdac7. ChIP-seq experiments will help us 
to verify if the absence of HDAC7 impairs the recruitment of HDACs and SMRT  in 
the transcriptional repressive complex on Cyp7a1 promoter and it might suggest 
the involvement of other transcriptional coactivators or corepressors, in turn 
regulated by Hdac7, which can contribute to the phenotypical evidences 
observed in H7LivKO mice. Moreover, it will allow to investigate the possible 
cross talk between HDAC7 and FGF15/19 pathway in light of previous evidences 
that showed that HDAC inhibitors prevent the repressive effect of FGF15/19 on 
Cyp7a1 promoter. Moreover, microarray analysis of H7LivKO mice compared to wt 
will reveal the effects of liver-specific HDAC7 ablation on global hepatic gene 
expression and it will elucidate possible changes in the expression of genes 
involved in lipid and lipoprotein metabolism that might be affected by the 
absence of HDAC7. In addition, H7LivKO serum will be analyzed by bidimensional 
electrophoresis and by quantitative FPLC to deepen lipoprotein changes.
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